Pharmaceutical composition comprising biopharmaceutical pharmaceutical compound

By preparing amorphous dry powder compositions, the stability and delivery efficiency issues of oral and mucosal drug delivery systems have been solved, achieving rapid absorption and stable delivery of active ingredients, suitable for intranasal, sublingual and other mucosal routes.

CN118973556APending Publication Date: 2024-11-15OREXO AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280088094.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-09-12
Filing Date
2022-11-25
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In existing technologies, oral and mucosal drug delivery systems have problems such as easy degradation of active ingredients by enzymes, first-pass metabolism in the liver, limited entry into the blood-brain barrier, long absorption time, high dose requirements, microbial instability, and difficulty in effectively delivering powder formulations. In particular, intranasal delivery presents challenges related to particle size and stability.

Method used

An amorphous dry powder composition containing a biopharmaceutical drug compound and a pharmaceutically acceptable carrier material is prepared as an amorphous single-particle powder by spray drying, ensuring the physical and chemical stability of the composition under normal storage conditions and making it suitable for transmucosa delivery.

Benefits of technology

It achieves rapid absorption of active ingredients, improves bioavailability, reduces side effects, enhances stability and dosage accuracy, and is suitable for intranasal, sublingual and other mucosal delivery routes, especially for the effective deposition and delivery of intranasal powder formulations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118973556A_ABST
    Figure CN118973556A_ABST
Patent Text Reader

Abstract

According to the present invention there is provided a composition in the form of an amorphous single particulate powder comprising a mixture of: (a) a pharmacologically effective dose of at least one biopharmaceutical pharmaceutical compound; and (b) a pharmaceutically acceptable carrier material comprising a combination of a disaccharide and a polymeric material. In this regard, the preferred pharmaceutically acceptable vehicle comprises lactose or trehalose and a dextrin (e.g., maltodextrin). The composition may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. The powder composition can be produced by combining the various components together for spray drying.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to novel pharmaceutical compositions comprising biopharmaceuticals useful for a variety of medical conditions. The present invention also relates to methods of making such compositions and formulating them into dosage forms. Background Art

[0002] The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an admission that the document is prior art or part of the common general knowledge.

[0003] Among the various well-known routes of drug delivery, oral delivery to the gastrointestinal tract is the most common. It is generally regarded as the most popular with patients and physicians.

[0004] However, oral drug administration is known to have disadvantages, including the fact that the active ingredient must undergo hepatic first-pass metabolism, enzymatic degradation within the gastrointestinal tract (as well as outside), and limited access to the blood-brain barrier (BBB) ​​to treat diseases of the central nervous system (CNS). These factors may not only affect the efficacy of certain drugs, but also make oral drug delivery completely impossible as a route of administration in some cases.

[0005] Oral administration to the gastrointestinal tract has the additional disadvantage that it requires absorption of the active ingredient by the intestine as part of the digestive process, which is time consuming. In addition, high doses of the active ingredient are usually required (due to low bioavailability), which carries the risk of more side effects and / or increased safety issues.

[0006] Finally, other limitations of oral formulations that limit their long-term use are microbial instability, which may require the use of preservatives to control, which may cause irritation and induce sensitization / allergic effects.

[0007] In the treatment of certain conditions, such as acute illness, it is often highly desirable to have a more rapid onset of pharmacological action than can be provided by oral drug delivery.

[0008] In such cases, the principle of administration in which the drug is immediately absorbed into the systemic circulation is more likely to result in a rapid onset of action. Although this can be accomplished via parenteral administration (such as subcutaneous or intravenous injection), such delivery means are inconvenient and sometimes extremely difficult and / or impossible for the patient to do, requiring time-consuming intervention by a physician to ensure compliance and avoid unnecessary or harmful effects.

[0009] Transmucosal administration of active ingredients is a viable alternative to parenteral administration. It creates the possibility of delivering drug molecules directly into the systemic circulation through the mucosa (e.g., rectal, sublingual, buccal, pulmonary, and intranasal), and may lead to advantages such as increased patient compliance, improved drug bioavailability and thus lower dosage, more rapid onset of action, and reduced side effects.

[0010] However, transmucosal administration of drugs presents its own rather significant problems. Unlike the gastrointestinal tract, which is a large organ containing relatively large amounts of biological fluids, spaces such as the oral and nasal cavities are relatively small and contain much smaller amounts of body fluids, such as saliva and / or mucus. This necessarily places considerable restrictions on the amount of active ingredient that can be administered in a single dose.

[0011] Furthermore, although the gastrointestinal tract is a dynamic system, it is in the main part somewhat like a 'closed' system. Conversely, the rapid clearance mechanisms occurring in both the oral and nasal cavities mean that for already more limited amounts of drug, the time available for absorption across mucosal surfaces is often also limited.

[0012] Many formulation principles have been proposed to address this problem, including, for example, bioadhesive formulation principles, such as buccal patches for oromucosal drug delivery (see, e.g., Shojaei, J. Pharm. Pharmaceutical Sci., 15, 19 (1998) and Gandhi, Advanced Drug Delivery Reviews, 43, 67 (1994)) and in situ gelling compositions for intranasal drug delivery (see, e.g., Bertan et al., Eur. J. Pharm. Sci., 27, 62 (2006)).

[0013] Transmucosal drug delivery systems in solid form can present significant advantages in allowing higher drug loading in the formulation. However, although solid drug delivery compositions are more common when administered to the rectal, buccal, sublingual and pulmonary mucosa, it is still the case that the vast majority of intranasal drug delivery systems are still presented in the form of liquid sprays, usually aqueous solutions, where drug solubility plays another limiting factor in the amount of drug available for absorption.

[0014] Such liquid sprays for intranasal delivery are almost universal, as it is not easy to formulate solid drug formulations in the form of nasal powders.Unlike powders, which are often employed to inhale the active ingredient into the lungs, there are very few commercially available intranasal powder formulations.

[0015] When formulated as a dry powder, pulmonary drug delivery compositions are usually in the form of an 'aggregate' mixture comprising micronized particles of the API on larger carrier particles. These aggregates are intended to dissociate / break down upon inhalation or actuation of the device, thereby depositing only fine particles of the active ingredient in the lungs.

[0016] However, such drug delivery systems are understood to be unable to work effectively in the case of intranasal drug delivery. This is because the presence of such fine particles results in a significant lung exposure risk, which is not the intended site of administration. If the drug particle size is increased in order to avoid this problem, it will be difficult to ensure the proper interaction in the heterogeneous 'interaction' mixture, which depends on the substantial difference in the size of the two components to ensure the interaction, which in turn leads to potential manufacturing problems, such as separation during filling. Attempting to compensate for this by correspondingly increasing the carrier particle size may not necessarily solve the problem, but will certainly increase the mass of the inactive excipients in the total mass of the dosage form with a limited limit, thereby likely causing a reduction in the dose of the active ingredient.

[0017] In U.S. Patent Application US2005 / 001411 A1, the difficulty of preparing dry powder for intranasal delivery is solved. In this document, the powder for nasal administration needs to be thin enough so that it can be effectively transported and effectively deposited in the nose by airflow, but also needs to be rough enough to help the powder to be introduced into a suitable powder device, which is always needed for intranasal administration. US2005 / 001411 A1 clearly solves this problem by making the loosely formed secondary particles (aggregates) of the primary particles containing the active ingredient. The dimension of this aggregate is hundreds of microns, and it is said that it can be loaded into a suitable intranasal administration (applicator, distributor or insufflator) device more effectively. When actuating this type of device and using the composition, the aggregate is obviously quickly decomposed into the primary particles of the active ingredient. The size of these primary particles is only a few microns, which is said to help it dissolve and the intranasal absorption of the active ingredient thereafter.

[0018] As stated above, transmucosal (e.g., intranasal) delivery of drugs intended for systemic absorption avoids first-pass metabolism, which is inevitably part of oral administration. Drug metabolism occurs through chemical reactions with enzymes that can change the chemical structure, physical structure, and / or biological activity of the active ingredient.

[0019] Since most drugs are organic molecules containing functional groups capable of undergoing such chemical reactions, they are often susceptible to some form of chemical breakdown when they come into contact with substances capable of interacting with those functional groups in vitro.

[0020] Such chemical transformations are often classified as chemical 'degradation' in the pharmaceutical art, as they can often result in loss of efficacy, or in extreme cases, the production of toxic by-products, either or both of which can render the drug ineffective and / or harmful to the patient.

[0021] The speed at which such degradation may occur depends, first of all, on the degree of inherent chemical instability of the drug compound, how it is formulated, and the conditions in which it is stored. High temperatures and humidity generally lead to accelerated degradation.

[0022] This loss of chemical integrity is measurable and is the reason that all drug products have a shelf life printed on their labels and / or embossed on their packaging. It is also the reason that some prescription drugs contain specific printed information in the package insert regarding appropriate storage conditions.

[0023] As a rule of thumb, the more complex the active ingredient, the greater the likelihood that chemical or physical integrity leading to biological inactivation will be an issue. In this regard, biologically active drugs / active pharmaceutical ingredients (APIs), such as vaccines, enzymes, antibodies / portions thereof, and antibody analogs and mimetics, for example, present particular problems because of their higher order (e.g., tertiary) structure and the interaction between being in proper conformation and effective function.

[0024] Furthermore, while proving increasingly useful for treating a wide range of diseases and disorders, certain biopharmaceuticals or biologics (such as antibodies / portions thereof) may not be particularly effective compared to other APIs that are small molecules and may require high doses to achieve significant biological effects.

[0025] As outlined by Kou and Zhou in Chapter 16 of the textbook Amorphous Solid Dispersions, Shah et al. (eds.), Springer (2014), if a drug is formulated in an amorphous form rather than in a crystalline physical state, it often exists in a higher energy state and may therefore be chemically and physically less stable, thus presenting challenges to the drug formulator.

[0026] Therefore, chemical stability is often improved by presenting the drug (particularly small molecules) in a crystalline state, often by salt formation. However, presenting large (macromolecule) biologics in such salt form is not a simple matter and is not usually an option in practice.

[0027]

[0006] Thus, in view of all of the foregoing potential advantages they offer, there remains a need for improved solid (eg, powder-based solid) transmucosal and, in particular, intranasal drug delivery systems.

[0028] In particular, there are still a large number of unmet clinical needs in the field of drug delivery for powdered drug delivery compositions that:

[0029] (i) be physically and chemically stable; and

[0030] (ii) providing active ingredients:

[0031] in adequate doses; and / or

[0032] If intended for systemic administration in this form, in this form it is sufficiently permeable to provide the desired therapeutic effect (such as speed of onset and / or access to the drug target) at the (relatively) low dose possible and with the short residence time available in a transmucosal setting (such as in the nasal cavity).

[0033] In addition to the above, in the more specific field of intranasal drug delivery, there remains a substantial unmet clinical need for drug delivery compositions comprising particles of appropriate size to be able to effectively:

[0034] Filling a drug delivery device; and

[0035] Deposition into relevant cavities (e.g. nasal cavity).

[0036] Intranasal dry powder formulations are known, inter alia, from international patent applications WO 2010 / 142696 and WO 2019 / 038756, US patent No. 10,653,690 B1 and US patent application US 2018 / 0092839A.

[0037] Spray drying of biologics has been disclosed, for example, in Bürki et al., Int. J. Pharm., 408, 248 (2011) and et al., supra, 543, 21(2018).

[0038] We have discovered that it is possible to formulate certain biologically active ingredients (i.e., biopharmaceuticals or biologics) in the form of amorphous dry powder compositions by methods such as spray drying of those active ingredients and specific combinations of carrier materials, as disclosed below. Such compositions can provide surprising and substantial improvements in the stability of those active ingredients prior to administration without significant loss in the pharmacological and / or biological activity of the relevant active ingredients. In addition, such compositions can provide improved bioavailability and / or absorption rate for those active ingredients after administration. Summary of the invention

[0039] According to a first aspect of the present invention, there is provided a pharmaceutically acceptable composition in the form of a solid amorphous single particle powder, comprising a mixture of:

[0040] (a) a pharmacologically effective amount of at least one biopharmaceutical drug compound; and

[0041] (b) a pharmaceutically acceptable carrier material comprising a combination of a disaccharide and a polymer material,

[0042] The pharmaceutically acceptable compositions are hereinafter collectively referred to as 'compositions of the present invention'.

[0043] The composition of the present invention is in the form of an amorphous single particle powder. 'Single particle' means that the plurality of particles forming the powdered composition of the present invention comprises a homogeneous or heterogeneous mixture, wherein the biopharmaceutical drug compound (also referred to herein as 'active ingredient', 'pharmaceutically active ingredient', 'pharmacologically active ingredient' and / or 'drug') is optionally encapsulated in an amorphous state in a carrier material as defined above in the presence of other ingredients. The particles of the powdered composition of the present invention are thus presented as an amorphous composite of the active ingredient, the carrier material and optionally the other ingredients.

[0044] Due to its amorphous nature, the composition of the present invention may be completely amorphous and / or may be predominantly amorphous (e.g., more than about 50% by weight, such as more than about 75% by weight, including more than about 80% by weight, such as more than about 90% by weight or 95% by weight, including more than about 99% by weight amorphous). In the alternative, the composition of the present invention may be less than about 50%, such as less than about 25%, more preferably less than about 20%, for example less than about 10%, including less than about 5% or less than about 1% crystalline. The crystallinity (%) may be determined by one skilled in the art using powder X-ray diffraction (PXRD). Other techniques may also be used, such as solid-state NMR, FT-IR, Raman spectroscopy, differential scanning calorimetry (DSC) microcalorimetry, and true density calculations.

[0045] As described below, despite being in an amorphous physical state, the compositions of the present invention exhibit remarkable and unexpected physical and chemical stability, and thus can be provided as pharmaceutical products that exhibit excellent shelf-life when stored under normal storage conditions.

[0046] The composition of the invention is prepared, at least initially, in multiparticulate form (i.e. as a powder) by a suitable technique. In general, suitable techniques are 'solvent-based' methods, which include spray drying, fluidized bed techniques, coprecipitation, supercritical fluid techniques, spray granulation, cryogenic techniques (including freeze drying), electrospinning and rotary jet techniques; or 'fusion-based' methods, which include melt granulation, melt extrusion, high shear mixing (e.g. ), milling and support technology for molten materials (e.g. ). Preferred methods include freeze drying, and more preferably, the composition of the present invention is prepared by a spray drying method.

[0047] Such powders may be suitable for direct delivery to a patient via any pharmaceutically acceptable route of administration, or may be presented as an intermediate composition that may subsequently be formulated into a pharmaceutically acceptable dosage form to be administered to one or more patients.

[0048] In this regard, there is provided a pharmaceutical formulation and / or a pharmaceutically acceptable dosage form to be administered to a patient and comprising one or more compositions of the invention.

[0049] Suitable pharmaceutical dosage forms may therefore include liquid preparations, such as solutions, which can be prepared by dissolving the composition of the invention in a pharmaceutically acceptable solvent, such as water (e.g., just before administration), for delivery to such patients, for example, by injection or by infusion. Such administration means may be useful when the active ingredient is an antibody, etc.

[0050] Alternative pharmaceutical dosage forms may include liquid or semisolid formulations such as liquid suspensions and / or gel compositions which may include a composition of the invention (e.g., particles thereof) suspended or dissolved in a suitable liquid or semisolid carrier which may be loaded into a suitable dosage form or delivered by, for example, injection or infusion or which may be formed following injection (e.g., subcutaneously or intramuscularly) to form an implant or depot formulation.

[0051] In an alternative, the composition of the invention may be presented as part of a substantially solid pharmaceutical dosage form. It will be well understood by those skilled in the art that the term 'solid' includes any form of matter that retains its shape and density when unrestrained and / or in which the molecules are generally packed as tightly as the repulsive forces between them allow. Thus, a substantially solid formulation is at least about 80%, such as at least about 90%, including at least about 95% (or at least about 99%) of such a form.

[0052] In this regard, the compositions of the present invention may be provided in any multiparticulate form (e.g., as simple powders, granules, pellets and / or beads), comprising a plurality of particles that may individually and / or collectively consist essentially of and / or comprise one or more compositions of the present invention.

[0053] Thus, the compositions of the invention may be presented following their preparation (eg, by spray drying) as simple powder mixtures, powder microspheres, coated powder microspheres, lyophilized liposomal dispersions, or a combination thereof.

[0054] If a pharmaceutically acceptable dosage form of the invention 'consists essentially of particles of one or more compositions of the invention', this will be understood to mean that the dosage form contains only one or more compositions of the invention, as well as other features and / or components that do not substantially affect the basic and novel characteristics of the dosage form. Alternatively, where a dosage form of the invention 'consists essentially of one or more compositions of the invention', this will be understood to mean that the dosage form contains at least about 90% by weight, such as at least about 95% by weight, including at least about 97% by weight (e.g., about 99% by weight) of those one or more compositions of the invention in total.

[0055] In the alternative, the pharmaceutical dosage form may comprise one or more compositions of the invention, which may be provided in a single unit dosage form, such as a pessary, a suppository or another form of insert, a pill, a capsule, a cake, a patch (e.g., a buccal patch), a film (e.g., an intraoral film), or a tablet (e.g., a sublingual tablet).

[0056] Capsules may be prepared by loading the composition of the invention as a spray-dried powder directly into a pharmaceutically acceptable capsule made of appropriate materials designed for sublingual or preferably oral delivery, or by mixing the composition with excipients prior to loading into such capsules, which may involve a granulation step as described below prior to loading into capsules for such delivery. Oral delivery may be employed when the active ingredient is, for example, an enzyme.

[0057] In this regard, the composition of the invention is granulated into pellets or pellets, but it can also be formulated (i.e., provided for administration) in the form of a dry free-flowing powder. 'Dry' includes substantially free of water and other liquid solvents, including less than about 10%, such as less than about 6%, including less than about 5%, or less than about 4%, more preferably less than about 3%, such as less than about 2%, for example less than about 1% of the formulation is liquid, such as water.

[0058] The flowability of the powder compositions of the invention may be measured by standard techniques known to those skilled in the art, including bulk density measurements, or measurements carried out on a powder flow analyser (e.g. those sold by Stable Micro Systems or Meritics, both UK), including tests of powder flow rate dependence, caking tests, cohesion tests, etc. A preferred measure of flowability is the standard angle of repose, which may be carried out using a rotating drum, stationary funnel or swing box.

[0059] In the context of the present invention, the term 'free flowing' is intended to include powders that allow efficient filling of the composition of the invention into a drug delivery device during manufacture and / or provide sufficient shot weight when discharged from the device (see below).

[0060] The term may also include powders exhibiting an angle of repose of no more than about 50°, such as no more than about 45°, including no more than about 40°, for example no more than about 35°, and more particularly no more than about 30°; a bulk density of no less than about 0.3 g / mL, for example no less than about 0.4 g / mL, such as no less than about 0.5 g / mL, and more particularly no less than about 0.6 g / mL; and / or a degree of compaction of no less than about 0.5 g / mL, such as no less than about 0.6 g / mL, for example no less than about 0.7 g / mL, and more particularly no less than about 0.8 g / mL.

[0061] Suitable techniques for making dosage forms comprising dry powders or granules include simple dry mixing, granulation (including dry granulation, wet granulation, melt granulation, thermoplastic pelletization, spray granulation), extrusion / spheronization, or, more preferably, freeze drying or spray drying (see below).

[0062] Dry granulation techniques are also well known to those skilled in the art and include any technique in which primary powder particles are agglomerated under high pressure, including packing and roller compaction, for example as described below.

[0063] Wet granulation techniques are also well known to those skilled in the art and include any technique involving the concentration of a mixture of dry primary powder particles using a granulating fluid comprising a volatile inert solvent such as water, ethanol or isopropanol, alone or in combination, and optionally in the presence of a binder or adhesive. The technique may involve forcing the wet mass through a screen to produce wet granules, which are then dried, preferably to a drying loss of less than about 3% by weight.

[0064] As will be known to those skilled in the art, melt granulation includes any technique in which particles are obtained by adding a molten binder or a solid binder that melts during the process (the binder material may comprise a pharmaceutically acceptable carrier material of the composition of the invention). After granulation, the binder solidifies at room temperature. Known thermoplastic pelletization will be similar to melt granulation, but in which the plastic properties of the binder are utilized. In both methods, the resulting agglomerates (particles) include a matrix structure.

[0065] As will be well known to those skilled in the art, extrusion / spheronization includes any process involving dry mixing of the ingredients, wet combining with a binder, extruding, spheronizing the extrudate into uniformly sized spheres, and drying.

[0066] As will be known to those skilled in the art, spray granulation includes any technique involving drying a liquid (solution, suspension, melt) while depositing particles in a fluidized bed. Thus, in addition to any general spray granulation technique, the term includes any method in which foreign seeds (germs) are provided and particles are deposited thereon, as well as methods in which intrinsic seeds (germs) are formed in the fluidized bed due to abrasion and / or rupture. The sprayed liquid coats the germs and contributes to further agglomeration of the particles. It is then dried to form particles in the form of a matrix.

[0067] The term 'freeze drying' includes lyophilization or freeze drying and any low temperature desolvation (eg dehydration) process in which the product is frozen, the pressure is reduced, and the frozen solvent (eg water) is removed by sublimation.

[0068] In an alternative, the composition of the present invention can be provided in the form of a tablet for oral, buccal and / or sublingual use. Such tablets can be formed, for example, by direct compression / compacting the composition of the present invention (optionally after it is mixed with one or more suitable excipients such as diluents, disintegrants, glidants and / or lubricants), and can be realized using techniques such as described in, for example, Pharmaceutical Dosage Forms: Tablets. Vol. 1, 3rd edition, Augsburger et al. (eds), CRC Press (2008) and the literature cited therein. Suitable compacting equipment includes standard pharmaceutical tablet machines, such as Kilian SP300 or Korsch EKO, XP1, XL 100 and XL 200.

[0069] Suitable disintegrants (as defined in, for example, Rowe et al., Handbook of Pharmaceutical Excipients, 6th edition (2009)) that may be employed in tablets include cellulose derivatives such as hydroxypropyl cellulose (HPC), low-substituted HPC, methyl cellulose, ethyl hydroxyethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, microcrystalline cellulose, modified cellulose gum; starch derivatives such as appropriately cross-linked starch, modified starch, hydroxypropyl starch, and pregelatinized starch; and other disintegrants such as calcium alginate, sodium alginate, alginic acid, chitosan, colloidal silicon dioxide, docusate sodium, guar gum, magnesium aluminum silicate, polacrilin potassium, and polyvinylpyrrolidone. Combinations of two or more disintegrants may be used.

[0070] Preferred disintegrants include so-called 'super disintegrants' (as defined in, for example, Mohanachandran et al., International Journal of Pharmaceutical Sciences Review and Research, 6, 105 (2011)) such as cross-linked polyvinyl pyrrolidone, sodium starch glycolate and cross-linked sodium carboxymethylcellulose. Combinations of two or more super disintegrants may be used.

[0071] When disintegrants and / or super disintegrants are used in tablets, they can be used in an amount (e.g., total amount) between 0.5% by weight and 15% by weight based on the total weight of the composition. A preferred range is 1% by weight to 8% by weight, such as about 2% by weight to about 7% by weight (e.g., about 5% by weight, such as about 4% by weight).

[0072] If present, the binder is preferably used in an amount between 0.5% and 20% by weight based on the gross weight of the tablet formulation. The preferred range is 1.0% to 15% by weight, such as about 2.0% to about 12% by weight (e.g., about 10% by weight). Suitable binders include cellulose gum and microcrystalline cellulose.

[0073] As described herein, the compositions of the present invention are preferably made by a spray drying process.

[0074] Whether in powder form or in other forms, the dosage form comprising the composition of the present invention can be prepared by standard techniques and using standard equipment known to those skilled in the art in other ways. In this regard, the composition of the present invention can be combined with conventional pharmaceutical additives and / or excipients used in the art for related preparations, and standard techniques are used to incorporate various types of pharmaceutical preparations to make dosage forms comprising the composition of the present invention (see, for example, Lachman et al., 'The Theory and Practice of Industrial Pharmacy', CBS, 4th edition (2015); 'Remington:The Science and Practice of Pharmacy', Troy (ed.), Elsevier, 23rd edition (2020); and / or 'Aulton's Pharmaceutics:The Design and Manufacture of Medicines', Taylor and Aulton (ed.), Elsevier, 5th edition, 2017).

[0075] Although the compositions of the invention are manufactured, preferably they are adapted and / or formulated for transmucosal delivery of the active ingredients into the systemic circulation (and, in the case of, for example, vaccines, generating a systemic immune response), or, again in the case of, for example, vaccines, generating an immune response in the local microenvironment.

[0076] Those skilled in the art will understand that the term 'transmucosal' means that although administered to a patient, the composition is presented at the relevant mucosal surface in a form across which the active ingredient can be absorbed after its dissolution. Relevant mucosal surfaces therefore include oral, nasal, ocular, vaginal, cervical, pulmonary and / or anorectal mucosa, more particularly, oral mucosa (including buccal and sublingual mucosa) and nasal mucosa.

[0077] Thus, dosage forms comprising the compositions of the invention can be administered directly to the mucosal surface of a patient (including pulmonary, rectal, vaginal, buccal, sublingual or intranasal) for transmucosal delivery of the active ingredient. Pulmonary and especially intranasal administration are particularly useful when the active ingredient is a vaccine, in which case transmucosal absorption may not necessarily elicit an immune response to the antigen.

[0078] If administered to the sublingual mucosa, the composition of the invention may be in the form of a sublingual tablet, for example as described above, which may contain a disintegrant or disintegrant (which may be defined as any material capable of accelerating the disintegration / dispersion of such a composition of the invention to a measurable extent), which may be achieved, for example, by a material capable of swelling and / or expanding when in contact with an aqueous medium as described below.

[0079] Alternatively, the compositions of the invention may be administered sublingually in the form of a powder as described herein, which may be poured into the mouth and under the tongue from a suitable container such as a capsule or sachet.

[0080] If the compositions of the invention are adapted and / or formulated for sublingual or, more particularly, intranasal administration, they are preferably administered in the form of a powder composition wherein the dose of the active ingredient does not exceed about 100 mg or does not exceed 10 9 International Units (IU). Such sublingual and / or nasal powder compositions may comprise the composition of the invention admixed with other excipients, or may consist essentially of the composition of the invention as defined above.

[0081] Compositions of the present invention suitable for and / or formulated for intranasal administration are preferably provided by a dosing member suitable for nasal delivery. Such dosing members may contain a spray-dried powder composition of the present invention, or may contain two or more such compositions. In the latter case, the dosing member contains two or more dosing amounts of the composition of the present invention, each of which will contain a pharmacologically effective dose of the active ingredient.

[0082] Two or more compositions of the invention may be administered intranasally by repeated actuation of a device comprising or communicating with the dosing member. Thus, the compositions of the invention may be present in a suitable device (e.g., a nasal applicator or dispenser (insufflator), e.g., as described below) and / or may be present in a container or reservoir that is part of, attached to, and / or suitable for attachment to such an applicator. Such a container or reservoir may contain one or more compositions of the invention, each of which contains a pharmacologically effective dose of the active ingredient.

[0083] In this way, an appropriate dosing member and / or nasal applicator can be actuated only once to deliver a single composition of the present invention comprising an appropriate dose of the active ingredient following such actuation (i.e., a single-use dosing unit), can be actuated more than once to deliver two or more compositions of the present invention each comprising an appropriate dose of the active ingredient upon each such actuation (i.e., multiple-use dosing units), and / or refilled with an alternative source of compositions of the present invention (e.g., a container or reservoir) comprising one or more such compositions to provide single doses and / or multiple doses and / or dosing regimens.

[0084] The composition of the invention may thus be applied in the form of a plurality of particles, which particles may individually and / or collectively consist of and / or comprise the composition of the invention.

[0085] The composition of the invention is therefore (initially) prepared in the form of a solid dry free-flowing multiparticulate powder, as described above.

[0086] As stated above, the composition of the present invention is provided in the form of an amorphous single particle powder. It is not composed of a physical combination of two or more discrete, separate particle collections of different components in the form of a mixture, such as an ordered or interactive mixture of smaller particles of the active ingredient combined with larger but separate and chemically different carrier material particles. That is, the composition of the present invention can be provided as small particles, which can then adhere to separate larger carrier particles in the interactive mixture, and if it is a dosage form intended for inhalation (e.g., inhalation into the lungs), such presentation may be useful (see, for example, J. Drug Delivery, Art. ID 5635010, 1-19 (2018)).

[0087] As mentioned above, the method of making the composition of the present invention enables the formation of a pharmaceutical product as defined herein that shows an excellent shelf life both in terms of physical and chemical stability when stored under normal storage conditions.

[0088] The composition of the present invention is preferably prepared by a spray drying process. Those skilled in the art will appreciate that the process of 'spray drying' includes any process for producing a dry powder from a liquid comprising a solution or suspension (including a slurry) which involves rapid drying using a hot gas to convert the liquid stream into an evaporated solvent and solid particles comprising solutes previously dissolved in the solution, and / or particles previously suspended in the evaporated liquid.

[0089] Suitable spray drying equipment includes some form of atomizing component, such as a nozzle, which disperses the liquid into a spray having a relatively uniform droplet size. Such components may include any component capable of producing a dry free-flowing powder, and may include a high-pressure vortex nozzle, a rotating disk and / or atomizer wheel, a high-pressure single-fluid nozzle, a two-fluid nozzle, and / or an ultrasonic nozzle.

[0090] The spray dryer may be a single-effect or multiple-effect spray dryer and may comprise an integrated and / or external vibrating fluidized bed, a particle separator and / or a collecting member which may be a rotating drum or a cyclone.

[0091] According to another aspect of the present invention, there is provided a method for producing the composition of the present invention, wherein the method comprises the following steps:

[0092] i) mixing one or more active ingredients and a pharmaceutically acceptable carrier material together in a suitable volatile solvent,

[0093] ii) spray drying the mixture from step i).

[0094] Preferred volatile solvents include water or organic solvents such as lower alkyl alcohols (e.g., methanol, isopropanol, or more particularly ethanol), hydrocarbons (e.g., C 5-10 Alkanes), halogenated alkanes (e.g., dichloromethane), dimethylformamide, dimethyl sulfoxide, ethyl acetate, acetone, etc., or mixtures thereof.

[0095] We prefer to mix one or more active ingredients, a pharmaceutically acceptable carrier material as defined herein and other optional ingredients as described herein (eg, an alkylsaccharide as described below) together with a solvent which produces a solution which can be spray dried.

[0096] Suitable pharmaceutically acceptable carrier materials that may be employed in the compositions of the present invention include relevant materials that are suitable for (and / or approved for) pharmaceutical use and / or transmucosal (e.g., sublingually or, in particular, intranasal) delivery in a solid state in appropriate combinations under normal storage conditions and that are capable of maintaining their physical and / or chemical integrity and / or do not affect the physical and / or chemical integrity of any active ingredient and / or any other ingredient that may be present in the composition (such as an alkyl saccharide).

[0097] As is well known, great difficulties may be encountered when attempting to obtain chemically and physically stable solid compositions such as powders. If the physical form of the composition changes under normal storage conditions (e.g., from a free-flowing powder to an agglomerated substance that is difficult to discharge), irreproducibility of the dose of the active ingredient may result. This is particularly true when dispensing the composition from or via a nasal applicator as described herein, where such agglomeration may result in a complete inability to dispense the active ingredient.

[0098] The compositions of the present invention may thus have a minimum shot weight of about 80%, such as about 85% (e.g., about 90%) up to about 120% (e.g., about 115%, such as about 110%) and / or an average powder shot weight relative to the target weight of about 85%, such as about 90% (e.g., about 95%) up to about 115% (e.g., about 110%, such as about 105%).

[0099] Similarly, for multiple dose units containing compositions of two or more doses, such stability is critical to ensure reproducibility of the dose of the active ingredient over time. Either of these issues may have an adverse effect on the health status of the subject and / or place the health of the subject at significant risk.

[0100] For certain compositions of the invention, exposure to atmospheric moisture may produce a powder composition with poor solid state stability. For example, exposure to certain (e.g., higher) relative humidities may affect the physical form of the composition, for example, by deliquescing, and / or by lowering the glass transition temperature of the composition and / or individual components of the composition (such as a carrier material), or in another way.

[0101] Therefore, the compositions of the present invention and pharmaceutical formulations and dosing components (such as nasal applicators) comprising the same are preferably packaged in containers that substantially prevent the ingress of atmospheric moisture under the storage conditions defined herein. Such containers may include packaging materials such as blister packaging for tablets and capsules and heat-sealed aluminum bags and / or thermoformed plastics. Such containers may also contain desiccants such as silica gel and / or appropriate molecular sieves, wherein the pore size is, for example, or

[0102] The phrase 'maintaining physical and chemical integrity' essentially means chemical stability and solid state stability.

[0103] 'Chemical stability' includes that any composition of the present invention can be stored as an isolated solid under normal storage conditions when formulated into a pharmaceutical formulation or dosage form and / or when loaded into a drug administration means, such as a nasal applicator or reservoir therefor (with or without appropriate pharmaceutical packaging), wherein the degree of chemical degradation or decomposition of the composition itself or the active ingredients included therein is not significant.

[0104] The term 'chemical stability' may also include 'stereochemical' and / or 'configurational' stability, by which is meant resistance to stereochemical transformations (such as racemization) at one or more chiral centres within the 'biopharmaceutical drug compound' molecule.

[0105] 'Physical stability' or 'solid state stability' includes that any composition of the present invention can be stored in an isolated solid form when formulated into a pharmaceutical formulation or dosage form and / or when loaded into a drug administration means (such as a nasal applicator or reservoir for use therein (with or without appropriate pharmaceutical packaging)) or otherwise under normal storage conditions, wherein the composition itself or the active ingredients included therein undergo no significant degree of solid state transformation (e.g., crystallization, recrystallization, loss of crystallinity, solid state phase transition (e.g., transformation between a glassy or rubbery state, or transformation to an aggregated form)), hydration, dehydration, solvation or desolvation. 'Physical stability' also includes the ability to maintain the correct conformation of a folded protein and / or the retention of biological activity as defined below.

[0106] Examples of 'normal storage conditions' for the compositions of the invention, whether in pharmaceutical formulation or dosage form, and / or when loaded into a drug administration member (which is loaded into an applicator, a device, a drug reservoir (such as a can or container)) or otherwise include a temperature between about -50°C and about +80°C (preferably between about -85°C (such as -25°C) and about +75°C, such as about 50°C), and / or a pressure between about 0.1 bar and about 2 bar (preferably atmospheric pressure), and / or exposure to about 460 lux of UV / visible light, and / or a relative humidity between about 5% and about 95% (preferably about 10% to about 40%), for an extended period of time (i.e. greater than or equal to about twelve months, such as about six months).

[0107] Under such conditions, it may be found that the composition of the present invention (and / or the active ingredient contained therein), whether or not included in a drug administration means (such as a nasal applicator or a reservoir therefor (with or without appropriate drug packaging)) or otherwise, is chemically degraded / decomposed as appropriate, and / or undergoes a solid state transformation of less than about 15%, more preferably less than about 10% and especially less than about 5%. The skilled person will understand that the upper and lower limits of temperature and pressure mentioned above represent extreme values ​​of normal storage conditions, and that certain combinations of these extreme values ​​will not be experienced during normal storage (e.g., a temperature of 50°C and a pressure of 0.1 bar).

[0108] Regardless of the above definition of 'normal storage conditions', the compositions of the present invention (and / or the active ingredients contained therein) may chemically (and / or stereochemically) degrade by less than about 5%, such as less than about 4% (including less than about 3%, such as less than about 2.5% (e.g., about 2%), including less than about 1.5% and even less than about 1%) after storage as follows:

[0109] (a) at about -85°C, including -25°C, such as 0°C or room temperature (e.g., about 20°C or about 25°C) or about 40°C and 75% relative humidity for at least about 3 months, including at least about 6 months or at least about 12 months;

[0110] (b) at a relative humidity of about 65%, such as about 60%, for example, for at least about 18 months, such as at least about 24 months, including at least about 36 months, at a temperature below about -85°C, including -25°C, such as 0°C, or room temperature (e.g., about 20°C or about 25°C) or about 30°C (at a relative humidity of about 65%, such as about 60%); and / or

[0111] (c) exposure to UV light greater than about 1 million lux for at least about 18 hours.

[0112] Such chemical and, in particular, physical stability is extremely important in solid compositions, such as powders, to ensure that an appropriate dose is delivered to the patient.

[0113] The compositions of the invention may thus be stored in a dosage form, such as an applicator or reservoir therefor (with or without appropriate pharmaceutical packaging) or otherwise at any temperature up to about 25°C (e.g., up to about 30°C) (e.g., as low as about -85°C, such as -25°C, including 0°C or 20°C), preferably with excursions of up to about 40°C or even up to about 50°C.

[0114] Particularly preferred pharmaceutically acceptable carrier materials which may be employed to produce the compositions of the present invention and which possess the desired characteristics mentioned herein include the disaccharide component, maltitol, sucralose, sucrose, isomalt, maltose, lactose and in particular trehalose.

[0115] For the polymer material component, preferred pharmaceutically acceptable carrier materials that can be used to produce the compositions of the present invention and have the desired characteristics mentioned herein include cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, cellulose acetate, hydroxypropyl methylcellulose (hydroxypropyl methylcellulose, HPMC), hydroxyethylcellulose (HEC), hydroxypropyl cellulose (HPC), methylcellulose (MC), ethyl hydroxyethylcellulose, carboxymethylcellulose (CMC), modified cellulose gum, microcrystalline cellulose and sodium carboxymethylcellulose; starches, such as rice starch, tapioca starch, wheat starch and more particularly, corn starch and potato starch; starch derivatives, such as pregelatinized starch, carboxymethyl starch and moderately cross-linked starch. starch, modified starch and sodium starch glycolate; polysaccharides, including dextran, pullulan, inulin and dextrins, such as dextrin, cyclodextrin and linear or branched dextrin, such as maltodextrin; powdered tragacanth; waxy excipients, such as cocoa butter and suppository wax; polyols, such as solid polyethylene glycol; acrylic acid polymers, such as carbomer and its derivatives; polyvinylpyrrolidone (povidone, PVP); cross-linked polyvinylpyrrolidone; polyethylene oxide (PEO); chitosan (poly-(D-glucosamine)); natural polymers, such as gelatin, sodium alginate, pectin; scleroglucan; xanthan gum; guar gum; poly-co-(methyl vinyl ether / maleic anhydride); and cross-linked carboxymethylcellulose (e.g., cross-linked carboxymethylcellulose sodium). Mention may also be made of hydroxypropyl methylcellulose acetate succinate (HPMCAS), copovidone and polyvinyl alcohol (PVA or PVOH).

[0116] More preferred polymer materials include sodium carboxymethylcellulose, sodium starch glycolate, polyvinylpyrrolidone and, in particular, hydroxypropyl methylcellulose (such as hydroxypropyl methylcellulose 2906, preferably hydroxypropyl methylcellulose 2910 (i.e., type 'E'), and more preferably USP / NF hydroxypropyl methylcellulose 2208 (i.e., type 'K'), etc., or in particular, polysaccharides, such as dextrins, including cyclodextrins (e.g., α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin and derivatives thereof, such as 2-hydroxypropyl-γ-cyclodextrin, sulfobutyl ether β-cyclodextrin sodium salt, randomly methylated β-cyclodextrin, branched β-cyclodextrin, etc., and in particular, 2-hydroxypropyl-β-cyclodextrin); and linear or branched dextrins, such as maltodextrin.

[0117] In any event, suitable polymers for use in the compositions of the invention should be of sufficiently high molecular weight that the polymer, when employed in any given amount in combination with the disaccharide, is capable of forming a carrier material for the active ingredient.

[0118] For any given polymer, the polymer chain length (and therefore the molecular weight) is directly proportional to its viscosity. In other words, the viscosity of a solution of that polymer is directly proportional to the molecular weight or chain length of the particular polymer.

[0119] In this regard, it may be preferred that the polymer has a relative viscosity value of no more than about 1000 (more preferably no more than about 120, such as no more than about 60, and especially no more than about 10) mPa*s at 20°C, as measured for any of the specified and substantially the following:

[0120] (a) A water-soluble polymer, such as a 2 wt% solution of the polymer in water, is prepared according to the standard USP method for viscosity, i.e. <911> Method I and / or <912> Method I; and

[0121] (b) A water-insoluble polymer, such as a 5 wt % solution of the polymer in a suitable organic solvent such as acetone, methanol, ethanol, isopropanol, ethyl acetate, acetonitrile, methylene chloride, toluene and mixtures thereof, the solvent system being dry or partially aqueous, according to USP method <911> Method I.

[0122] One skilled in the art will understand which test is more appropriate for the polymer being tested.

[0123] Preferably, the support material is capable of producing a composition of the present invention having a glass transition temperature (Tg) of:

[0124] (a) enabling its production as a hard and / or brittle, 'glassy', amorphous, powdery physical form which can be readily formulated into a pharmaceutical formulation or dosage form, and / or loaded into a suitable drug delivery means (such as a nasal applicator), or a drug reservoir and / or container within or attached to such an applicator as described herein; and

[0125] (b) sufficiently high that after such pharmaceutical formulation, dosage form, or drug delivery member (such as an applicator or reservoir) is packaged as described herein and thereafter subjected to high external temperatures (e.g., up to between about 50°C and about 80°C), it remains in the glassy state rather than transforming into a more viscous or rubbery state and / or a crystalline state.

[0126] In warm and / or sunny climates, such extreme external temperatures are usually experienced inside the medium, and these mediums will often be placed for a long time under sufficient sunlight, and the heat increase generated therein can be huge. If the Tg of the composition of the present invention (e.g., powder) is low, the composition can be transformed into such a viscous / rubber state after being exposed to such high temperatures, which will lead to the inefficient administration of the composition of the present invention, such as once the administration member or applicator is actuated, the composition is discharged inefficiently (and the dosage of the active ingredient is also the same) from the administration member (such as the applicator or the reservoir for it). In addition, too low Tg may affect the disintegration and / or dissolution of the composition of the present invention in the form of a tablet for sublingual or oral use.

[0127] In this regard, we prefer that the lowest measurable Tg of the composition of the present invention is at least about 10°C, such as at least about 15°C, such as at least about 20°C, including at least about 25°C, such as at least about 35°C, including at least about 40°C, such as at least about 50°C, such as at least about 55°C, including at least about 60°C, when measured at a relative humidity of up to about 35%, such as up to about 30%, including up to about 25% (e.g., up to about 20%, such as below about 15%, for example below about 10%). 'Lowest measurable Tg' includes that the composition of the present invention may include particles that are heterogeneous in nature. In particular, the particles may include discrete regions of a carrier material or a composite mixture thereof, and may therefore have individual and separate Tg values. It will be clear to those skilled in the art that the value of the lowest measurable Tg has a strong influence on the physical stability of the composition.

[0128] We have found in particular that the compositions of the present invention comprising a combination of a disaccharide and a polymer (e.g. HPMC as defined herein) and / or in particular dextrin, when taken alone or in isolation, are able to produce an appropriate level of physical and chemical stability of the composition and active ingredient when compared to other carrier materials.

[0129] Particularly preferred combinations of carrier materials therefore include lactose, such as α-D-lactose monohydrate, or more preferably trehalose and dextrins and especially cyclodextrins, such as 2-hydroxypropyl-β-cyclodextrin, or maltodextrins, wherein the DE is above 11, such as maltodextrin 12DE, or above 15, such as maltodextrin 19DE. We have found that such combinations of carrier materials can be spray dried with the active ingredient and, if present, an appropriate proportion of an alkyl saccharide to produce a composition of the invention as defined herein having both the desired physical and chemical stability under normal storage conditions.

[0130] We have found that the relative amounts of the disaccharide and polymer components in the carrier material (and particularly therefore when the polymer is a dextrin) can be adjusted to ensure the desired level of physical and / or chemical stability of the active ingredient, while not lowering the Tg of the composition of the invention in a way that affects its physical stability.

[0131] We have found that a ratio of disaccharide:polymer (e.g., dextrin) between about 50:1 to about 1:50 by weight, based on the total weight of the composition, may work depending on the active ingredient employed. A preferred ratio of disaccharide:polymer (e.g., dextrin) by weight, based on the total weight of the composition, is from about 10:1 to about 1:40 (including up to about 1:30 or up to about 1:20), for example, between about 7:1 (including about 5:1, such as about 4:1, about 3:1, or about 2:1) and about 1:10 (such as about 1:8, including about 1:5, for example 1:3 or 1:2), more preferably in the range of about 8:1 (e.g., about 7:1, about 3:1, about 2:1, or about 1:1) to about 1:8 (e.g., about 1:3 or about 1:2).

[0132] Particularly preferred combinations of carrier materials therefore comprise trehalose or lactose, such as α-D-lactose monohydrate, and dextrins, and in particular cyclodextrins, such as 2-hydroxypropyl-β-cyclodextrin, or more preferably, maltodextrin.

[0133] Maltodextrins are classified by DE (dextrose value), wherein the higher the DE value, the shorter the average length of the glucose chains.

[0134] Preferred maltodextrins include maltodextrins having a DE between 6 and 15 (such as 8 and 12) or above 15, for example up to 47, such as 38, 39, preferably 23, 24, 25 or 26, or more preferably 16, 17, 18, 20, 21 or 22, and especially 19. Those skilled in the art will appreciate that maltodextrins having a DE above 20 are referred to as 'glucose syrups'.

[0135] Maltodextrins with a DE above 15 have a lower average molecular weight than maltodextrins with a DE of 15 or less. All maltodextrins are mixtures of polysaccharides with different chain lengths, and maltodextrins with a DE above 15 have fewer larger molecular weight sugar units.

[0136] We have found that maltodextrins with lower DE (such as maltodextrins with DE of 12 or less) contain longer polysaccharide chains (e.g., having greater than or equal to about 24 glucose units) that have a tendency to form helical structures that can form aggregates when present in aqueous solution with other components (such as active ingredients and / or surfactants, such as sucrose esters), resulting in a turbid liquid prior to spray drying. This turbidity can cause stability and / or processability issues during manufacturing, necessitating the use of inline filters.

[0137] Although we have found that the above-mentioned turbidity problem can be alleviated to some extent by reducing the relative amount of maltodextrin included in the composition of the present invention, which can be achieved by increasing the amount of other ingredients (such as other carrier materials (e.g. disaccharides), active ingredients or certain additives (such as sucrose esters), the higher the molecular weight of the maltodextrin, the less maltodextrin needs to be included and the more (e.g.) disaccharides or sucrose esters need to be added to alleviate turbidity.

[0138] If more sucrose ester is added in order to reduce the turbidity, it may be necessary to add more sucrose ester than is required to provide the appropriate (e.g., physical, chemical and / or biological) effects (including absorption enhancing effects), as mentioned herein. Conversely, increasing the amount of disaccharide relative to maltodextrin in the carrier material may have a negative impact on the Tg, and therefore on the solid state stability of the composition as described herein.

[0139] We have found that such problems can be reduced and possibly avoided altogether by using a different maltodextrin together, ie a maltodextrin with a higher DE, such as a maltodextrin with a DE above 15 (eg DE 18, 20 or more preferably 19).

[0140] Notwithstanding the above, polymers comprising maltodextrin suitable for use in the powder compositions described herein should still have a high enough molecular weight such that when the polymer is employed in any given amount (in combination with the disaccharide), it is able to form a suitable carrier material for the active ingredient, including providing an appropriate degree of physical stability.

[0141] Mixtures from any of the above list of disaccharides and / or polymeric materials (including maltodextrin) may be employed.

[0142] The amount of carrier material that can be employed in the compositions of the present invention is generally in the range of about 5 wt % to about 99.9 wt %, including up to about 99 wt % (e.g., up to about 95 wt % or about 90 wt %), such as about 10 wt % (e.g., about 25 wt %, including about 35 wt %) to about 85 wt %, including about 50 wt % to about 75 wt %, based on the total weight of the composition (regardless of whether a dose of the composition is included in a dosing member or otherwise).

[0143] Regardless of their proportions in the final mixture, the composition of the present invention comprises a spray-dried carrier material comprising a combination of a disaccharide and a polymeric material (e.g., dextrin). Thus, the carrier material may be prepared by spray drying the relevant ingredients to form a composite carrier material, or before spray drying the carrier material together with other essential ingredients to form the composition of the present invention, or more preferably, in situ by spray drying all essential components of the composition of the present invention together. The composition of the present invention may be prepared by spray drying in the presence of a processing aid such as L-leucine, isoleucine, trileucine, L-tyrosine, or L-arginine.

[0144] The composition of the invention may comprise at least one biopharmaceutical drug compound.'Biopharmaceutical drug compound' within this definition also includes biopharmaceuticals or biologics, wherein the biopharmaceutical drug compound is produced by a living organism or a product thereof, or comprises a component of a living organism.

[0145] Biopharmaceutical drug compounds include proteins and / or oligopeptides or polypeptides, enzymes, antibodies / parts thereof, vaccines, nucleotides, etc. or antibody analogs, antibody mimetics, immunoglobulins, immunomodulators or combinations thereof. Biopharmaceutical drug compounds may also include blood (e.g., blood cells suspended in plasma), blood components (e.g., human blood components), cells, allergens (e.g., pollen, dust mites, animal dander, mold, drugs, insect venom, and various foods), genes, viruses (e.g., animal viruses, plant viruses, bacterial viruses, bacteriophages, archaeal viruses, helper viruses, fungal viruses, neurotropic viruses, novel viruses, emerging viruses, tumor viruses, orphan viruses, passenger viruses, proviruses, retroviruses, lentiviruses, DNA viruses, dsDNA viruses, dsDNA-RT viruses, dsRNA viruses, nuclear cytoplasmic large DNA viruses (NCLDV), antisense ssRNA viruses, RNA viruses, ssDNA viruses, ssRNA viruses, satellite viruses (including single-stranded RNA satellite viruses, double-stranded DNA satellite viruses, and single-stranded DNA satellite viruses), pathogens, Toxin bodies, virus particles, virus-like particles, capsid virus particles, viral components and / or elements (such as capsids, capsomers, endogenous viral elements (EVEs), nucleocapsids), toxins (e.g., toxins from bacteria (such as anthrax lethal toxin, botulinum toxin, pertussis toxin, Staphylococcus aureus enterotoxin B (SEB)), fungi and algae (such as aflatoxin, saxitoxin, saxitoxin, scoparia toxin, deoxynivalenol (deoxynivalenol), fumonisin diacetate, T-2 and HT-2 toxins), plants (such as abrin and ricin), venom (e.g., neurotoxins, hemotoxins, cytotoxins), or combinations thereof. Such biological agents or biological preparations can be used to treat or prevent one or more primary indications selected from the following group: oncological diseases, cardiovascular diseases, infectious diseases, autoimmune or inflammatory diseases, metabolic diseases.

[0146] It should be understood that such proteins and / or oligopeptides or polypeptides that can be used include naturally occurring proteins and / or oligopeptides or polypeptides and their synthetic analogs, semisynthetic, synthetic proteases. Preferably, such proteins and / or oligopeptides or polypeptides are naturally occurring, or are recombinant proteins and / or peptides. More preferably, such proteins, oligopeptides and / or polypeptides have a molecular weight of more than 5 kDa, such as more than 10 kDa, for example more than 20 kDa, including more than 30 kDa.

[0147] Types of naturally occurring proteins, oligopeptides and / or polypeptides include cytoskeletal proteins such as myosin, Arp2 / 3, Arp2 / 3, coronin, dystrophin, dystrophin, FtsZ, geranin, keratin, myosin, tubulin; extracellular matrix proteins such as collagen, elastin, floor plate reaction protein, pikachu protein, fibronectin; globular proteins such as plasma proteins (e.g., serum amyloid P component); coagulation factors such as complement proteins (e.g., C1-inhibitor, C3-convertase), factor XIII, protein C, protein S, protein Z, protein Z-related protease inhibitor, thrombin, hemophilic factor; acute phase proteins (e.g., C-reactive protein); heme proteins (e.g., hemoglobin); cell adhesion proteins (e.g., cadherins, ependymin, integrins, NCAM, selectins); transmembrane transporters (e.g., CFTR, glycophorin D, scrambled enzymes); ion channels (e.g., potassium channels, calcium channels, sodium channels, glucose transporters); hormones and growth factors (e.g., colony stimulating factor (CSF), epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF), vascular endothelial growth factor (VEGF), transmembrane receptors (e.g., rhodopsin); intracellular receptors (e.g., estrogen receptor body); DNA binding proteins (e.g., histones, protamine); transcription and regulatory proteins (e.g., CI protein, C-myc, FOXP2, FOXP3, MyoD, P53); RNA binding proteins (e.g., SRRT); immune system proteins (e.g., immunoglobulins, major histocompatibility antigens, T cell receptors); nutrient storage and / or transport proteins (e.g., ferritin); chaperones (e.g., GroEL); cytokines and analogs (including recombinant cytokines), such as IL-1 receptor antagonists, anakinra, IL-4, IL-6, IL-10, IL-12, IL-17, IL-23, IL-27, IL-33, IL-35 or more particularly, IL-2, IL-7, IL-15 or IL-21, TNF-α, IFN-α, pilofenadine, mobekin, adaleukin α, aldesleukin, simoleukin, denileukin, pergoleukin, tesileukin, tocotaxolumab simoleukin, danistin, molestim, human interleukin, atileukin α, emoleukin, iloleukin, oprelleukin, eduleukin α, simoleukin, iboveleukin, cytokines developed as protein therapeutics (e.g., bone morphogenetic protein (BMP), granulocyte colony stimulating factor (G-CSF), interferon α, IL-11);Enzymes (e.g., oxidoreductases, transferases, hydrolases, lyases, isomerases, conjugating enzymes), zymogens (e.g., angiotensinogen, trypsinogen, chymotrypsinogen, pepsinogen, prothrombin, plasminogen, procaspase, pacifastin, proelastase, prolipase, carboxypeptidase), such as α-glucosidase, α-D-galactosidase, β-glucocerebrosidase, iduronic acid-2-sulfatase, n-acetylgalactosamine-6-sulfatase, n-acetylgalactosamine-4-sulfatase, pancreatic enzymes Products (PEP) containing pancreatic lipase, a mixture of digestive enzymes, lipase, protease and amylase; alteplase, reteplase and tenecteplase; dornase alfa, begolotidase, rasburicase, L-asparaginase, collagenase, pegadase (bovine), brancarpase, okroplasmin; and lactase (from Aspergillus oryzae, Aspergillus niger, Kluyveromyces fragilis, Kluyveromyces lactis or Escherichia coli); human peptide hormones such as anti-Mullerian hormone, adiponectin, adrenocorticotropic hormone, angiotensinogen, angiotensin II, vasopressin, antidiuretic hormone, atrial natriuretic hormone peptides, cholecystokinin, corticotropin-releasing hormone, corticostatin, endothelin, follicle-stimulating hormone, galanin, gastrin, glucagon-like peptide-1, glucagon and glucagon-like peptide-1 analogs, dasiglitazone, gonadotropin-releasing hormone, growth hormone-releasing hormone, hepcidin, human chorionic gonadotropin, human placental lactogen, growth hormone, inhibin, leptin, lipotropin, luteinizing hormone, melanocyte stimulating hormone, enterokinin, orexin, osteocalcin, pancreatic polypeptide, prolactin, prolactin-releasing hormone, relaxin, renin, Growth hormone-inhibiting hormone, somatotropin-releasing hormone, somatotropin-releasing factor, somatotropin-releasing hormone, thrombopoietin, thyroid-stimulating hormone, thyrotropin, thyrotropin-releasing hormone, guanylin, uroguanylin, tetrakosaktid, mecasermin, somapacitan, pegvisomant, desmopressin, terlipressin, lysine vasopressin, ornithine vasopressin, arginine vasopressin, desmotocin, carbetocin, octreotide, vapreotide, ikatocin, or a combination thereof. ;

[0148] Other types of proteins, oligopeptides and / or polypeptides may include viral or bacterial proteins. The term 'viral or bacterial protein' includes proteins that are both components and products of viruses or bacteria and are preferably encoded by viral or bacterial genomes. Preferably, the viral protein is a component of the capsid or envelope of the virus. The viral protein may be the (S) spike protein of a coronavirus or a portion or variant thereof; the hemagglutinin (H) or neuraminidase (N) protein of an influenza virus or a portion or variant thereof; the L3 protein of an adenovirus or a portion or variant thereof; the fusion protein of a respiratory syncytial virus (RSV) or a portion or variant thereof.

[0149] Preferably, the protein, oligopeptide or polypeptide is not human insulin, cyclosporine, insulin, interferon beta, interferon gamma, TPA, albumin, HGH, factor VIII, erythropoietin, calcitonin, oxytocin, vasopressin, cyclosporine, substance P, anal fold frog peptide, neurokinin A, octopus salivary gland sperm, neurokinin B, VIP (vasoactive intestinal peptide; PHM27), PACAP (pituitary adenylate cyclase activating peptide), peptide PHI 27 (histidine isoleucine 27), GHRH 1-24 (growth hormone-releasing hormone 1-24), glucagon, secretin, NPY (neuropeptide Y), PYY (peptide YY), APP (avian pancreatic polypeptide), PPY pancreatic polypeptide, pro-opiomelanocortin (POMC) peptide, endomorphin, enkephalin pentapeptide, pro-dynorphin peptide, calcitonin, dextrin, AGG01, B-type natriuretic peptide (BNP) lactotripeptide, peptide components from: traditional Chinese medicine donkey-hide gelatin, buserelin, gonadorelin, goserelin, histrelin, leuprorelin, nafarelin, triptorelin, abarelix, cetrorelix, degarelix , ganirelix, elagolix, relagolix, teverelix, desmopressin, liraglutide, exenatide, lixisenatide, albiglutide, dulaglutide, semaglutide, somatostatin and analogs, octreotide, pasireotide, lanreotide, teriparatide, or a peptide comprising one or more of the following: buserelin, gonarelin, goserelin, histrelin, leuprolide, nafarelin, triptorelin, abarelix, cetrorelix, degarelix, ganirelix, elagolix, relagolix, teverelix, leuprolide, liraglutide, octreotide, desmopressin.

[0150] Biopharmaceutical drug compounds that can be used in the compositions of the present invention also include antibodies. The term 'antibody' will be understood to include polyclonal antibodies and monoclonal antibodies. The term also includes all isotypes of antibodies, such as: IgG, IgA, IgM, IgD and IgE. Although the antibody can be a polyclonal antibody, it is preferably a monoclonal antibody.

[0151] In some cases, particularly if the antibody is to be repeatedly administered to a human patient, it is preferred that the monoclonal antibody is a human monoclonal antibody or a humanized monoclonal antibody. Suitable monoclonal antibodies can be prepared by known techniques, such as described in 'Monoclonal Antibodies Meeting the Challenges in Manufacturing, Formulation, Delivery and Stability of Final Drug Product' Steven Shire, (Woodhead Publishing, 2015), Current Trends in Monoclonal Antibody Development and Manufacturing', Shire et al. (Springer New York, 2010), 'Therapeutic Monoclonal Antibodies: From Bench to Clinic', Zhiqiang An (Wiley 2009), 'Monoclonal Antibodies; A manual of techniques', H Zola (CRC Press, 1988) and 'Monoclonal Hybridoma Antibodies: Techniques and Application', SGR Hurrell (CRC Press, 1982), the relevant disclosures of which are hereby incorporated by reference. Polyclonal antibodies can be produced that are either multispecific or monospecific.

[0152] In one embodiment, the antibody may be a murine antibody, a human (including humanized) antibody, or a chimeric antibody. Chimeric antibodies are discussed by Neuberger et al. (1998, 8th International Biotechnology Symposium Part 2, 792-799), and the relevant disclosures in the document are hereby incorporated by reference. Appropriately prepared non-human antibodies can be 'humanized' in a known manner, for example, by inserting the complementary determining regions (CDRs) of mouse antibodies into the framework of human antibodies. An antibody can be a human antibody in the following sense: the antibody has the amino acid sequence of a human antibody specific for a desired antigen or antigenic epitope, but can be prepared using methods known in the art that do not require human immunization. For example, transgenic mice containing substantially human immunoglobulin genes can be used (see Vaughan et al. (1998) Nature Biotechnol. 16, 535-539), and the relevant disclosures in the document are hereby incorporated by reference.

[0153] Non-limiting examples of (monoclonal) antibodies that can be used according to the invention are edrecolomab (L01XC01), tositumomab (V10XA53), rituximab (L01XC02), basiliximab (LO4AC02), infliximab (L04AB02), adalimumab (L04AB04), ibritumomab tiuxetan (V10XX02), vedolizumab (L04AA33), trastuzumab (L01XC03), gemtuzumab ozogamicin (L01XC05), cetuximab (L01XC06), bevacizumab (L01XC07), panitumumab (L01XC08) , denosumab (M05BX04), eloumab (C10AX13), brodalumab (L04AC12), erenumab (N02CD01), captocinomab (L01XC09), ofatumumab (L01XC10), ipilimumab (L01XC11), erenumab-aooe, brentuximab vedotin (L01XC12), pertuzumab (L01XC13), trastuzumab emtansine (L01XC14), atezolizumab (L01XC15), dinutumumab beta (L01XC16), nivolumab (L01XC17), natalizumab ( L04AA23), ixekizumab (L04AC13), reslizumab (R03DX08), dupilumab (D11AH05), pembrolizumab (L01XC18), blinatumomab (L01XC19), ramucirumab (L01XC21), nexitozumab (L01XC22), elotuzumab (L01XC23), daratumumab (L01XC24), moglizumab (L01XC25), inotuzumab ogamicin (L01XC26), olatumomab (L01XC27), durvalumab (L01XC28), bemectizumab (L01XC29). C29), avelumab (L01XC31), atezolizumab (L01XC32), cemiplimab (L01XC33), pacitumomab (L01XC34), dafacitinib (L01XC35), enrofloxacin (L01XC36), plotuzumab vedotin (L01XC37), isatuximab (L01XC38), berantuzumab mafodotan (L01XC39), dotalimumab (L01XC40), trastuzumab derutokan (L01XC41), bispecific T-cell engagers (BiTEs; such as blinatumomab, solituzumab, AMG 330, MT112, MT111, BAY2010112, MEDI-565, remanezumab, ganezumab-gnlm, eprannezumab-jjmr, ustekinumab, eculizumab, omalizumab, or a combination thereof.

[0154] Other non-limiting examples of antibodies that can be used according to the present invention include etanercept, tocilizumab, siltuximab, ceruleumab, olozumab, sirukumab, tirazumab, guselkumab, BI-655066, LY3074828, secukinumab, CNTO6785, bimegezumab, SCH-900117, MLDL1278A, bucurizumab, brianuzumab, muromonab, abciximab, alemtuzumab, certolizumab pegol, canakinumab, belimumab, edascept, and sirukumab. izumab, mepolizumab, alirocumab, orizumab, emicizumab, benralizumab, brosuzumab, lanarizumab, imatinib, ibalizumab, ravulizumab, lomosozumab, risakizumab, brosuzumab, clirizumab, gosatuzumab, efaizumab, nebacumab, daclizumab, omalizumab, ustekinumab, trastuzumab-emtansine conjugate, trastuzumab derutokan, satelizumab, inbilizumab, tetumumab, ivannab Anti-, ervantumab, trorocirumab, anifolumab, lantuximab terin, atevimab, matevimab, ociviromab-EBGN, magetuximab-CMKB, azuvetumab-ZYKL, aducanumab, aducanumab-AVWA, remdavimab, sotravirumab, tesotumomab vedotin, tesotumomab vedotin-TFTV, tezepelumab, tezepelumab-EKKO, tebentuximab, tebentuximab-TEBN, faretuzumab, faretuzumab-SV oa, sutuzumab, sutuzumab-jome, relimab, tesagvir, cegavir, carrelizumab, imivir, tislelizumab, obeluzumab, sibsolizumab, necevir, terituzumab, utoximab, moxentuzumab, tremelimumab, penampalimumab, lencanerumab, inomucomab, tilizumab, donetumab, metuximab soraftensin, toripalimab, sintilimab, rivulizumab, omopluzumab monatoxin, nasolizumab, or a combination thereof

[0155] Biopharmaceutical drug compounds that can be used in the compositions of the present invention also include antibody mimetics. Non-limiting examples of antibody mimetics that can be used include affibody molecules (such as ABY-025), aphirin (such as SPVF 2801), aphimo, aphidin, alpha bodies (such as CMPX-1023), anticalins, high affinity multimers, designer ankyrin repeat proteins (DARPins, such as MP0112), fenomo, Kunitz domain peptides (such as Kalbitor), Adnectin and monofunctional bodies (such as Angiocept), nanoCLAMP, single domain antibodies (such as camelid antibodies), and V of IgNAR (immunoglobulin new antigen receptor) obtained from cartilaginous fish.NAR fragments, bivalent single domain antibodies (such as Cablivi); and armadillo repeat proteins, hereinafter referred to as designer armadillo repeat proteins, peptide aptamers and knottins, or a combination thereof.

[0156] In alternative embodiments, the compositions of the invention comprise antibody-derived molecules such as antibody fragments (F(ab); e.g., ranibizumab (S01LA04)), bivalent antibody fragments (F(ab')2), and related molecules such as variable fragments (Fv) and other fragments thereof that retain an antigen binding site, single-chain variable fragments (scFv) (which may be bivalent (e.g., diabodies) or trivalent), single domain antibodies (dAbs), or combinations thereof. 'Bivalent' means that antibodies, antibody mimetics, antibody-derived molecules, and related molecules have two antigen binding sites. In contrast, monovalent molecules will have only one antigen combining site. A general review of the techniques involved in synthesizing antibody-derived molecules that retain their specific binding sites is to be found in Winter & Milstein (1991) Nature 349, 293-299.

[0157] 'ScFv molecules' include those wherein V H and V L The partner domain is connected via a molecule of flexible oligopeptide. The advantages of using antibody-derived molecules rather than whole antibodies are multiple. The smaller size of the fragment can lead to improved pharmacological properties, such as better penetration to the target site. The effector functions of the whole antibody are removed, such as complement fixation. Fab, Fv, ScFv and dAb antibody-derived molecules can all be expressed in and secreted from antibody-derived molecules, thus allowing easy production of large quantities of molecules.

[0158] It will be appreciated that such antibodies, antibody mimetics, antibody-derived molecules and related molecules can be monospecific, bispecific or multispecific or a combination thereof. The inclusion of bispecific or multispecific means that it binds to two or more different targets.

[0159] The term 'antibody' also includes antibody-like molecules, which can be screened and selected using in vivo and in vitro based selection methods. Such selection methods include yeast surface display, prokaryotic or bacterial surface display, mammalian surface display, ribosome display, mRNA display, cDNA display, CIS display, covalent antibody display (CAD), in vitro compartment formation (IVC) and phage display technology or other random selection techniques for molecules.

[0160] Biopharmaceutical drug compounds that can be used in the compositions of the present invention also include the following antibodies / immunoglobulins: common human immunoglobulin for extravascular administration (J06BA01); common human immunoglobulin for intravascular administration (J06BA02); anti-D (rh) immunoglobulin (J06BB01); tetanus immunoglobulin (J06BB02); varicella / herpes zoster immunoglobulin (J06BB03); hepatitis B immunoglobulin (J06BB04); rabies immunoglobulin (J06BB05); rubella immunoglobulin (J06BB06); pox immunoglobulin (J06BB07); staphylococcal immunoglobulin (J06BB08); Cytomegalovirus immune globulin (J06BB09); diphtheria immune globulin (J06BB10); hepatitis A immune globulin (J06BB11); encephalitis; insect-borne immune globulin (J06BB12); pertussis immune globulin (J06BB13); measles immune globulin (J06BB14); mumps immune globulin (J06BB15); palivizumab (J06BB16); movimedumab (J06BB17); lanxibanumab (J06BB18), betzlotinumab (J06BB21); otosaximab (J06BB22); anthrax immune globulin (J06BB19); combination (J06BB30); or a combination thereof.

[0161] The compositions of the present invention are particularly useful when the biopharmaceutical drug compound comprises one or more vaccines.

[0162] When considering improving vaccination programs in developing countries, cost is a significant factor. One way to reduce vaccine costs is to produce more stable vaccine compositions, wherein such compositions do not require a cold chain, for example making them cheaper and easier to transport and store. In addition, it is believed that the loss of activity of vaccines under suboptimal storage conditions significantly leads to less effective vaccination programs (Brandau et al., 2003). The World Health Organization (WHO) requires that vaccine formulations have a minimum potency after storage at 37°C for one week. However, many vaccines may lose more than 50% of their potency when stored at room temperature for only 1 hour (Plotkin & Orenstein, 2004).

[0163] In one embodiment, the vaccine can be a live or active vaccine, an attenuated vaccine, a live attenuated vaccine (e.g., measles, mumps and rubella (MMR) vaccine, varicella vaccine), an inactivated or killed vaccine (e.g., polio vaccine, influenza vaccine).

[0164] In one embodiment, the vaccine may be a whole pathogen vaccine, a subunit vaccine, or a nucleic acid vaccine, such as a live attenuated vaccine, an inactivated vaccine, a subunit vaccine, a recombinant vaccine, a polysaccharide vaccine, a conjugate vaccine, a toxoid vaccine, a viral vector vaccine, and / or a messenger RNA (mRNA) vaccine.

[0165] In another embodiment, the vaccine may be a subunit vaccine (such as a protein subunit vaccine, e.g., a recombinant vaccine or a virus-like particle (VLP) vaccine (including capsid-like virus particles, virus-like particles derived from viral capsids) against, for example, hepatitis B, acellular pertussis vaccine influenza, HIV, HPV, malaria, gonorrhea, polio, Zika virus, smallpox, monkeypox, various types of cancer (such as those expressing and / or overexpressing HER2 (human epidermal growth factor receptor 2), EGFR (epidermal growth factor receptor), CD-20, VEGF (vascular endothelial growth factor), VEGFR (vascular endothelial growth factor receptor), CEA (carcinoembryonic antigen), CA-125 (cancer cell proliferation factor receptor), ... Antigen 125), MUC-1 (mucin 1) or MAGE (melanoma associated antigen) cancer), more specifically, acute respiratory diseases caused by viruses (including respiratory syncytial virus (RSV) or coronavirus (including variants of either virus)), such as acute respiratory distress syndrome (ARDS) and / or severe acute respiratory syndrome (SARS), and especially COVID-19, or, for example, wherein the protein is the (S) spike protein or a portion thereof; polysaccharide vaccines, such as pneumococcal polysaccharide vaccines, meningococcal vaccines; or conjugate vaccines, such as pneumococcal conjugate vaccines, Haemophilus influenzae type b conjugate vaccines, meningococcal conjugate vaccines, MenACWY). Subunit vaccines can be produced in different systems, such as E. coli systems, yeast cell systems, insect cell systems, plant systems or mammalian cell systems.

[0166] In yet another embodiment, the vaccine may be a nucleic acid vaccine (such as a DNA vaccine or an RNA vaccine, preferably wherein the RNA is messenger RNA (mRNA)). Examples of such vaccines may include anti-cancer DNA vaccines, DNA vaccines against tuberculosis, DNA vaccines against Edwardsiella tarda, DNA vaccines against HIV, DNA vaccines against anthrax, DNA vaccines against influenza, DNA vaccines against dengue fever, DNA vaccines against typhoid fever, DNA vaccines against different antigens (e.g., p CE6 、p CE18, iniae Streptococcus DNA vaccines in the form of plasmid pSia10, pIDSia10, pIDOmpU, pSiVa1, etc.), prophylactic DNA vaccines, non-replicating mRNA vaccines, in vivo self-replicating mRNA vaccines, in vitro dendritic cell non-replicating mRNA vaccines, dendritic cell vaccines, personalized cancer vaccines (for example, in which the RNA sequences in the vaccine are designed to encode cancer-specific antigens), RNA vaccines against SARS diseases (such as diseases caused by the coronavirus SARS-CoV-2, i.e., coronavirus 2019 or COVID-19).

[0167] In yet another embodiment, the vaccine may be a toxoid vaccine (e.g., tetanus toxoid (TT) vaccine; diphtheria vaccine; diphtheria, pertussis and tetanus (DPT) vaccine; or botulinum toxoid vaccine). For the avoidance of doubt, toxoid vaccines include toxoid vaccines that use toxins made by, for example, disease-causing germs.

[0168] In yet another embodiment, the vaccine may be a viral vector vaccine. The viral vector may be a poxvirus (e.g., vaccinia virus, modified Ankara vaccine virus (MVA), avian pox virus, fowl pox virus), a retrovirus (e.g., lentivirus), vesicular stomatitis virus (VSV), measles virus, adenovirus, adeno-associated virus, cytomegalovirus, Sendai virus, herpes simplex virus, or a combination thereof. The viral vector may be a live or active viral vaccine, an attenuated viral vaccine, a live attenuated viral vaccine, an inactivated vaccine, or an inactivated viral vaccine.

[0169] In yet another embodiment, the vaccine can be a bacterial carrier vaccine. The bacterial carrier can be lactic acid bacteria Mycobacterium bovis BCG, Lactococcus lactis, Salmonella, Salmonella, Bacillus subtilis, Pseudomonas aeruginosa, Shigella, Shigella, Vibrio cholerae, Vibrio anguillarum, Corynebacterium pseudotuberculosis, Bordetella pertussis, Streptococcus, Listeria monocytogenes, Escherichia coli, Yersinia enteritidis, Mycobacterium smegmatis, Lactobacillus or a combination thereof.

[0170] In yet another embodiment, the vaccine may be a conjugate vaccine against bacterial infection, such as pneumococcal infection.

[0171] In yet another embodiment, the vaccine may be a recombinant vector vaccine.

[0172] In yet another embodiment, the vaccine may be a nanoparticle-based vaccine (such as a mesoporous silica nanoparticle (MSN)-based vaccine or a solid lipid nanoparticle (sLNP)-based vaccine), or a virus-like particle (VLP) vaccine (e.g., a capsid VLP vaccine or a viral capsid-derived VLP vaccine), each of which may be effective against diseases including influenza, HIV, HPV, malaria, gonorrhea, polio, Zika virus, smallpox virus, monkeypox virus, bacterial infections (such as Chlamydia trachomatis, Neisseria gonorrhoeae, Neisseria meningitidis, Bordetella pertussis, or Mycobacterium tuberculosis), or various types of cancer (such as those that express and / or overexpress HER2 (human epidermal growth factor-2). The invention relates to cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs, particularly cancers of the lungs Nanoparticle-based or VLP-based vaccines can also carry and / or deliver proteins or parts thereof (such as viruses, bacteria, mammals, fungi or parasitic proteins, which can be membrane proteins, surface proteins, fusion proteins, envelope proteins, structural proteins, spike proteins, nucleocapsid or capsid proteins or combinations thereof), DNA, lipids, polysaccharides, toxins (such as bacterial toxins), mRNA, RNA or viral vaccines (such as live virus vaccines, attenuated virus vaccines, live attenuated virus vaccines, inactivated virus vaccines). Nanoparticle-based or VLP-based vaccines can also further carry and / or deliver adjuvants and immunostimulatory molecules, such as TLR agonists and cytokines.

[0173] Alternatively, the composition of the present invention in the form of a vaccine composition may include an adjuvant. The term 'adjuvant' is intended to mean any compound added to a formulation to increase the biological effects of one or more products of the present invention in the formulation. The adjuvant may be one or more of zinc, copper or silver salts with different anions, such as but not limited to fluoride, chloride, bromide, iodide, cyanate, sulfite, hydroxide, phosphate, carbonate, lactate, glycolate, citrate, borate, tartrate and acetate of different acyl compositions. The adjuvant may also be an organic polycation (e.g. polyethyleneimine (PEI)), a cationic polymer such as cationic cellulose ether, cationic cellulose ester, deacetylated hyaluronic acid, chitosan, a cationic dendrimer, a cationic synthetic polymer such as poly (vinyl imidazole), a cationic polypeptide such as polyhistidine, polylysine, polyarginine and peptides containing these amino acids, cations (N3) or anions (L3) lipid adjuvants. Depending on the host species, a variety of adjuvants can be used to increase immune response.Such adjuvants include, but are not limited to, toxoid adjuvants, cytokines, natural killer T cell (NKT) ligands (e.g., α-galactocerebroside (αGalCer) and the like), C-type lectin receptor (CLR) ligands, toll-like receptor (TLR) agonists (e.g., CpG, CpG ODN, Poly I:C, glucopyranosyl lipid A (GLA), monophosphoryl lipid A (MPL), resiquimod (R848), flagellin, imidazoquinoline (e.g., imiquimod), STING ligands (e.g., STING agonist: bis-(3',5')-cyclic dimeric guanosine monophosphate (c-di-GMP or cdGMP)), muramyl dipeptide, EP 109942, EP 180564 and EP 231039, 'immunostimulatory complex', surfactants such as lysolecithin, polyanions, peptides, hemocyanin (e.g. KLH), aluminum salts, alum, Alhydrogel, aluminum hydroxide, aluminum phosphate, saponin-based adjuvants (e.g. Matrix M1), delta inulin microparticle adjuvants (e.g. Advax), DEAE-dextran, neutral oils (e.g. miglyol), vegetable oils (e.g. peanut oil), squalene (e.g. shark squalene) emulsions (e.g. MF59, AS03, Freund's complete or incomplete adjuvant, Montanide ISA51, Montanide ISA720), liposomes (e.g., DOPE (1,2-di-(9Z-octadecanoyl)-sn-glycero-3-phosphoethanolamine): DDA (dimethyldioctadecyl ammonium bromide) multilamellar liposomes, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP) liposomes), lipid nanoparticles, poly(lactic-co-glycolic acid) (PLGA) nanoparticles, Pluronic polyols or Ribi adjuvant systems, nucleic acids (e.g., single-stranded RNA), Hiltonol, or combinations thereof. 'Pluronic', 'Alhydrogel', 'Hiltonol', 'Montanide' are registered trademarks.

[0174] Such vaccines will be suitable for use in vaccinating against, reducing the risk of, preventing or combating diseases, disorders and / or conditions. The diseases, disorders and / or conditions may, for example, be caused by viral, bacterial and / or parasitic infections. Alternatively, the diseases, disorders and / or conditions may have endogenous and / or genetic environmental causes, including autoimmune diseases, cardiovascular diseases, inflammatory diseases, metabolic diseases and / or cancers.

[0175] In preferred embodiments, the virus causing the disease, illness and / or condition may be an orthomyxovirus (e.g., influenza virus, such as influenza A(H1N1), A(H3N2), A(H7N7), A(H3N8); infectious salmon anemia virus or togo virus), a parvovirus (e.g., adeno-associated virus, canine parvovirus (CPV), panleukopenia (FPV), mink enteritis virus (MEV)), an adenovirus, a pneumovirus (e.g., respiratory syncytial virus (RSV)), a herpesvirus (e.g., herpes simplex virus (HSV), feline herpesvirus type 1 (FHV-1), equine herpesvirus (EHV), varicella zoster virus), a rubella virus (e.g., rubella virus), a rhabdovirus (rabies virus), a retrovirus (e.g., lentivirus, human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV)), Poxvirus (e.g., poxvirus, smallpox virus, monkeypox virus), paramyxovirus (e.g., measles virus, Newcastle disease virus, mumps virus, canine distemper virus (CDV), canine parainfluenza virus (CPi)), papillomavirus (e.g., human papillomavirus (HPV)), reovirus (e.g., rotavirus), picornavirus (e.g., poliovirus, hepatovirus A virus, hepatovirus B virus), calicivirus (e.g., Norwalk virus, sapovirus, vesicular exanthema virus, such as feline calicivirus (FCV)), norovirus, flavivirus (e.g., West Nile virus, dengue virus, tick-borne encephalitis virus, yellow fever virus, Zika virus, Japanese encephalitis virus), togavirus (e.g., alphavirus), or coronavirus (e.g., severe acute respiratory syndrome coronavirus, such as SARS-CoV-1 or SARS-CoV-2).

[0176] In a preferred embodiment, the bacterium can be a coccal bacterium (e.g., Chlamydia trachomatis, Neisseria gonorrhoeae, Neisseria meningitidis, Staphylococcus aureus, Staphylococcus haemolyticus, Streptococcus agalactiae, Streptococcus bovis, Streptococcus equi, Streptococcus pyogenes), a Bacillus bacterium (e.g., Bacillus anthracis, Bordetella pertussis, Bordetella bronchiseptica, Chlamydia pneumoniae, Clostridium tetani, Corynebacterium diphtheriae, Legionella pneumophila, Mycobacterium leprae, Mycobacterium tuberculosis, Vibrio cholerae, Rickettsia), a spiral (spiral or spirochete) bacterium (e.g., Borrelia burgdorferi, Leptospira, Leptospira renii, Treponema pallidum, Treponema denticola), Neorickettsia rickettsii, or a mycoplasma (e.g., Mycoplasma gallisepticum, Mycoplasma hyopneumoniae).

[0177] In preferred embodiments, the parasite may be a protozoan (eg, Giardia, Plasmodium), a helminth (eg, flatworms, nematodes), or an ectoparasite (eg, ticks, fleas, lice, mites).

[0178] In a preferred embodiment, the autoimmune disease can be uveitis, atopic dermatitis, hidradenitis suppurativa, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, type 1 diabetes, myasthenia gravis, Guillain-Barre syndrome, osteoarthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, paroxysmal nocturnal hemoglobinuria, neuromyelitis optica, chronic idiopathic urticaria, migraine or cystic fibrosis.

[0179] In one embodiment, the cancer may be a carcinoma, a sarcoma, a lymphoma, a leukemia, a germ cell cancer or a blastoma. Preferably, the cancer may be a bone and muscle cancer, a cancer of the brain and nervous system (e.g., glioblastoma, glioma, neuroblastoma, chordoma), a breast cancer (e.g., breast cancer, medullary carcinoma, phyllodes tumor), a cancer of the endocrine system (e.g., thyroid cancer, multiple endocrine neoplasia syndrome, adrenocortical carcinoma), an eye cancer (e.g., uveal melanoma, retinoblastoma, optic nerve glioma), a gastrointestinal cancer (e.g., gastric (abdominal) cancer, colon cancer, rectal cancer, colorectal cancer, pancreatic cancer, liver cancer, gallbladder cancer), a genitourinary cancer and a gynecological cancer (e.g., bladder cancer, uterine cancer). The following are some of the cancers that are included in the list: (i) ovarian cancer, ovarian cancer, renal cell carcinoma, prostate cancer, Wilms tumor, urothelial bladder cancer, (ii) head and neck cancer (e.g., head and neck cancer, esophageal cancer, pharyngeal cancer, oral cancer), (iii) hematopoietic cancer (Hodgkin's lymphoma, AIDS-related lymphoma, acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma), (iv) skin cancer (e.g., melanoma, basal cell carcinoma, squamous cell skin cancer, keratoacanthoma), (v) chest and respiratory cancer (e.g., small cell lung cancer, non-small cell lung cancer, pleuropulmonary blastoma), and (v) anti-angiogenic cancer (e.g., HIV / AIDS-related cancer).

[0180] In another embodiment, the cancer may express and / or overexpress one or more tumor-associated antigens, such as HER2 (human epidermal growth factor receptor 2), EGFR (epidermal growth factor receptor), CD-20, VEGF (vascular endothelial growth factor), VEGFR (vascular endothelial growth factor receptor), CEA (carcinoembryonic antigen), CA-125 (cancer antigen 125), MUC-1 (mucin 1), MAGE (melanoma-associated antigen).

[0181] Thus, examples of vaccines may include injectable polio vaccine (Salk vaccine), hepatitis A vaccine, rabies vaccine (e.g., canine, feline or human rabies vaccine), influenza vaccine (e.g., equine influenza vaccine), tick-borne encephalitis vaccine), Eastern and Western equine encephalitis vaccine (EEE / WEE), coronavirus (e.g., SARS-coronavirus) vaccines (including BBIBP-CorV, CoronaVac, Covaxin, QazVac, TURKOVAC, CoviVac), injectable typhoid vaccine, cholera vaccine, plague vaccine, pertussis vaccine, anthrax vaccine, cholera vaccine, plague vaccine, salmonella vaccine, tuberculosis vaccine, typhoid vaccine, enterotoxigenic Escherichia coli vaccine, live attenuated influenza vaccine (LAIV), such as FLUMIST, Japanese encephalitis vaccine, measles vaccine, mumps vaccine, measles and rubella (MR) vaccine, measles, mumps and rubella (MMR) vaccine, measles, mumps, rubella and varicella (MMRV) vaccine, polio vaccine, rotavirus vaccine, rubella vaccine, smallpox vaccine, varicella vaccine, yellow fever vaccine, herpes zoster vaccine, tick-borne encephalitis vaccine, COVID-19), mRNA vaccines, toxoid vaccines (e.g., tetanus toxoid, diphtheria toxoid, botulinum toxoid), viral vector vaccines, DNA vaccines, recombinant vector vaccines, subunit vaccines (comprising protein subunits, such as hepatitis B, acellular pertussis vaccines, polysaccharides, such as pneumococcal polysaccharide vaccines, meningococcal vaccines or combinations, such as pneumococcal conjugate vaccine, Haemophilus influenzae type b conjugate vaccine, meningococcal conjugate vaccine), recombinant vaccines, conjugate vaccines, and vaccine adjuvants or combinations thereof.

[0182] Other examples of vaccines include Ebola virus vaccine, Zika virus vaccine, poxvirus vaccine (e.g., monkeypox virus vaccine), RSV vaccine, HIV vaccine, feline rhinotracheitis (FVR) vaccine, equine West Nile virus vaccine, Potomac horse fever (PHF) vaccine, equine herpes virus vaccine, malaria vaccine (e.g., RTS, S / AS01 or ) or anticancer vaccines (e.g. T-VEC Sipuleucel-T, CVAC-301 CV9104, MVA.5T4, MVA-BN(R)-HER2, DCVax-L, TAEK-VAC-HerBy, ChAdOx1-MAGEA3-NYESO, Redopitide, and vaccines against HER2 and brachycodal cancers).

[0183] In some embodiments, the vaccine may be administered to the subject only once. In other embodiments, the vaccine may be administered to the subject two or more times. For example, in embodiments where the vaccine is an inactivated, subunit, recombinant, polysaccharide, conjugate, or toxoid vaccine, it may be appropriate to administer a primary dose and one or more subsequent booster doses to the subject, respectively.

[0184] In some embodiments, a vaccine may be administered to a subject in combination with another type of biopharmaceutical drug compound (e.g., an antibody). Thus, immunization may include components of active and / or passive immunity. Active immunity results after exposure to an antigen, while passive immunity provides immunity passively (e.g., via preformed antibodies produced exogenously (e.g., from another host)).

[0185] Immunotherapy, optionally wherein the immunotherapy is oncolytic virotherapy. Oncolytic virotherapy (OV) includes forms of immunotherapy that refer to the use of competent replication viruses to infect and destroy cancer cells. Preferably, the competent virus specifically attacks tumor cells rather than healthy cells.

[0186] The compositions of the present invention may also contain:

[0187] Antigens including exogenous, endogenous and self-antigens or a combination thereof; and / or

[0188] Viral vectors comprising retroviruses (eg, lentiviruses), poxviruses, adenoviruses, and adeno-associated viruses (AAV)), or a combination thereof.

[0189] Biopharmaceutical drug compounds that can be employed in the compositions of the present invention also include oligonucleotides, including aptamers (including DNA, RNA, XNA or peptide aptamers), molefino, CpG oligodeoxynucleotides, polypurine reverse-Hosted hairpins or combinations thereof; and nucleotides (e.g., adenosine monophosphate (AMP), guanosine monophosphate (GMP), cytosine monophosphate (CMP), uridine monophosphate (UMP), cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), cyclic cytosine monophosphate (cCMP), cyclic uridine monophosphate (cUMP), deoxyadenosine monophosphate (dAMP), deoxyguanosine monophosphate (dGMP), deoxycytidine monophosphate (dCMP), (deoxy)thymidine monophosphate (dTMP), adenosine diphosphate (ADP), guanosine diphosphate (GDP), cytosine diphosphate (CDP) , uridine diphosphate (UDP), deoxyadenosine diphosphate (dADP), deoxyguanosine diphosphate (dGDP), deoxycytidine diphosphate (dCDP), (deoxy)thymidine diphosphate (dTDP), adenosine triphosphate (ATP), guanosine triphosphate (GTP), cytidine triphosphate (CTP), uridine triphosphate (UTP), deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate (dGTP), deoxycytidine triphosphate (dCTP), (deoxy)thymidine triphosphate (dTTP)), nucleosides and corresponding nucleobases (e.g., adenine, adenosine, deoxyadenosine, guanine, guanosine, deoxyguanosine, thymine, 5-methyluridine, thymidine, uracil, uridine, deoxyuridine, cytosine, cytosine, deoxycytidine), antisense components (e.g., antisense oligonucleotides, antisense RNA), siRNA therapeutic agents (e.g., (Patishnan) and GIVLAARI TM (givosiran), mRNA therapeutics, DNA therapeutics, or a combination thereof.

[0190] Biopharmaceutical drug compounds that can be employed in the compositions of the present invention also include immunomodulators, such as interleukins (e.g., IL-2, IL-7, IL-12, IL-27, IL-4, IL-10, IL-35, IL-33), cytokines (e.g., interferon, G-CSF), chemokines (e.g., CCL3, CCL26, CXCL7), cytosine phosphate-guanosine, oligodeoxynucleotides, dextran, or a combination thereof.

[0191] Additionally, and / or in the alternative, preferred biopharmaceutical drug compounds that may be employed in the compositions of the present invention include compounds (listed above or otherwise) having a water solubility of at least about 10 mg / mL, such as at least about 1 mg / mL, including at least about 100 μg / mL, such as at least about 10 μg / mL, for example at least about 1 μg / mL and particularly at least about 0.5 μg / mL, for example at least about 0.1 μg / mL, such as at least about 0.05 μg / mL and particularly at least about 0.01 μg / mL at room temperature and atmospheric pressure. 'Water solubility' will be understood to include not only solubility in pure water, but also solubility in relevant physiological fluids, and particularly solubility found in the nose (which can also be simulated with respect to isotonicity and pH).

[0192] Preferred active ingredients that can be used in the composition of the present invention include the fusion protein Alatuscept and the following antibodies: Pembrolizumab, Adalimumab, Ustekinumab, Trastuzumab, Bevacizumab, Rituximab, Nivolumab, Infliximab, Eculizumab, Omalizumab, Cetuximab and Panitumumab, Remanetuzumab, Ganecuzumab-GNLM and Epranetuzumab-JJMR; The following enzymes: Alteplase, Reteplase, Tenecteplase, Dornase Alpha, Begoloic Acid, Rasburicase and L-asparaginase; and the following vaccines: typhoid vaccine, pertussis vaccine, cholera vaccine, tuberculosis vaccine, typhoid vaccine, measles, mumps and / or rubella (including MMR) vaccine, polio vaccine, yellow fever vaccine, zoster / shingles vaccine, tetanus toxoid, diphtheria toxoid and botulinum toxoid vaccine, and in particular influenza vaccine and SARS-coronavirus (e.g. SARS-CoV-2) vaccine.

[0193] Other active ingredients that may be employed in the compositions of the present invention include carcinoembryonic antigen (CEA), cancer-related tumor markers such as cancer antigen 125 (CA-125), mucin 1 (MUC-1), melanoma-associated antigen (MAGE).

[0194] Combinations of one or more of the foregoing active ingredients of the same or different classes may be employed.

[0195] When the composition of the present invention is made by a solvent-based method as described above (including by a spray drying method), this may cause the active ingredient to no longer exist in the form of a crystalline salt, because it is freely dispersed in the carrier material and encapsulated by the carrier material in an amorphous form. The composition of the present invention can cause minimal to no loss of chemical stability of the active ingredient under normal storage conditions mentioned herein.

[0196] Furthermore, when prepared in this manner, the biopharmaceutical drug compound present in the composition of the invention may have substantially the same biological activity when compared to the biopharmaceutical drug compound in isolated form prior to manufacture of the relevant composition. 'Substantially the same biological activity' includes a loss of less than about 95%, such as less than about 90%, including less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 20%, less than about 25%, less than about 20% or about 15%, and particularly less than about 10% (depending on the biopharmaceutical drug compound employed, the biological activity may include potency, binding activity and / or pharmacological effects, such as immune response), as can be measured by appropriate assays for the biopharmaceutical drug compound in question, for example, as described below.

[0197] In addition, when formulated into a pharmaceutical formulation or dosage form, and / or when loaded into a pharmaceutical administration means (such as a nasal applicator or a reservoir therefor (with or without appropriate pharmaceutical packaging)) or otherwise under ordinary storage conditions as defined above, the compositions of the present invention can be stored in isolated solid form, wherein the degree of loss of biological activity of the biopharmaceutical drug compound is not significant (e.g., the loss of biological activity of the biopharmaceutical drug compound is less than about 95%, such as less than about 90%, including less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 20%, less than about 25%, less than about 20% or about 15%, and in particular less than about 10%), as can be measured by an appropriate assay for the biopharmaceutical drug compound in question, for example, as described below.

[0198] The amount of active ingredient that can be used in a single dose of the composition of the present invention must be sufficient to exert its pharmacological effect. For the composition of the present invention administered through the mucosa (e.g., sublingually, buccally and especially intranasally), the amount shall not exceed about 100 mg in a single dose. The actual dose of the above-mentioned related biopharmaceutical drug compound is included in the medical literature known in the art and can be discussed in such as Martindale-The Complete Drug Reference, 40th edition, Pharmaceutical Press, London (2020) and the documents mentioned therein (the relevant disclosures in all documents are hereby incorporated by reference) Those doses described in the active ingredient. However, compared with the prior art compositions comprising the same active ingredient, it can be found that the composition of the present invention exhibits good bioavailability and / or rapid absorption, thereby causing a faster onset and / or higher plasma concentration.

[0199] In this regard, the pharmacologically appropriate amount of active ingredient in the composition of the present invention may be lower than those mentioned in the literature (see above). Nevertheless, such amounts can be determined by the skilled person and may vary with the type and severity of the condition to be treated and the degree that is most suitable for the individual patient. This may also vary with the nature of the formulation and the type and severity of the condition to be treated, as well as the age, weight, sex, renal function, liver function and response of the respective patient to be treated.

[0200] Depending on the potency of the biopharmaceutical drug compound, and depending on the final dosage form to be used, the total amount of active ingredients that can be employed in the composition of the present invention can be based on the total weight of the composition, about 0.0001% by weight or about 0.0002% by weight, for example about 0.001% by weight, such as about 0.01% by weight, including about 0.1% by weight (e.g., about 1%, about 2%, or about 5%) by weight, such as about 10% by weight (e.g., about 20%) by weight up to about 95% by weight, such as about 75% by weight, for example about 50% by weight, for example about 40% by weight. This is independent of the number of individual doses (which should be the same) of the composition initially present in the administration member of the present invention.

[0201] For transmucosal (including pulmonary, buccal, sublingual or preferably intranasal) administration, appropriate dosages of the active ingredient per unit dose (calculated as free acid / base) are from about 0.01 μg, such as about 0.1 μg, including about 1 μg (e.g. about 10 μg, such as about 250 μg) up to about 100 mg (e.g. about 80 mg), such as between about 1 mg and about 60 mg (e.g. about 3 mg, such as about 10 mg to about 50 mg), depending on the active ingredient employed.

[0202] For other forms of administration (e.g., by injection or oral administration), depending on the active ingredient employed, a suitable dose of the active ingredient per unit dose (calculated as free acid / base) is in the range of about 1 μg to about 1,000 mg, such as about 500 mg (e.g., about 400 mg), such as between about 1 mg and about 300 mg (e.g., about 3 mg, such as about 10 mg to about 200 mg).

[0203] Alternatively, the appropriate dose of the active ingredient may be based on the biological activity or action of the different biopharmaceuticals (i.e., proteins, oligopeptides, polypeptides, enzymes, antibodies and portions thereof, vaccines, nucleotides and analogs thereof, antibody analogs, antibody mimetics, immunoglobulins, immunomodulators, blood, blood components, cells, allergens, genes, viruses, toxins, venoms, or combinations thereof) (rather than the mass of the biopharmaceutical compound). The appropriate dose may be about 10 -9 International Units (IU) to approximately 1x10 9 The International Unit (IU) includes the amount of active ingredient that produces a specified effect when tested according to internationally recognized standardized biological procedures (see World Health Organization (WHO) International Standards). Methods for calculating appropriate IUs depending on different biopharmaceutical compounds will be known to those skilled in the art.

[0204] According to three further aspects of the present invention, there are provided:

[0205] a composition of the invention for use in treating a condition for which at least one biopharmaceutical drug compound comprised therein is indicated (e.g. by transmucosal, such as intranasal, administration of the composition);

[0206] Use of a composition of the invention for the manufacture of a medicament (e.g. transmucosal, such as intranasal) for the treatment of a condition for which at least one biopharmaceutical drug compound contained therein is indicated; and

[0207] - A method of treating a condition for which at least one biopharmaceutical drug compound contained in a composition of the invention is indicated, the method comprising administering (e.g. transmucosally, such as intranasally) a composition of the invention to a patient suffering from or susceptible to the condition.

[0208] Depending on the nature of the active ingredients comprised in such compositions, the compositions of the invention are useful for treating a wide range of clinical conditions, including rheumatoid arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, multiple sclerosis, diabetic retinopathy, age-related macular degeneration, diabetes, diabetes insipidus, cancer, as well as psoriatic arthritis and chronic obstructive pulmonary disease (COPD).

[0209] Compositions of the invention comprising, for example, alasercept and adalimumab (anti-TNF(α) agent) can be used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis; compositions of the invention comprising, for example, ranibizumab and aflibercept can be used to treat diabetic retinopathy and age-related macular degeneration; compositions of the invention comprising, for example, adalimumab can be used to treat psoriasis and ankylosing spondylitis; compositions of the invention comprising, for example, cetuximab and panitumumab can be used to treat The composition of the present invention comprising pembrolizumab (anti-PD-1 agent) can be used to treat melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin's lymphoma, gastric cancer, cervical cancer, urothelial carcinoma, colorectal cancer, renal cell carcinoma and breast cancer; the composition of the present invention comprising ustekinumab (anti-interleukin (IL)-12 / 23 agent) can be used to treat psoriasis; the composition of the present invention comprising trastuzumab (anti-HER2 agent) can be used to treat breast cancer; the composition of the present invention comprising bevacizumab (anti-VEGF agent) can be used to treat colorectal cancer; The composition of the present invention containing rituximab (anti-CD20 agent) can be used to treat non-Hodgkin's lymphoma; the composition of the present invention containing nivolumab (anti-PD1 agent) can be used to treat melanoma, non-small cell lung cancer, renal cell carcinoma and head and neck cancer; the composition of the present invention containing infliximab (anti-TNF(α) agent) can be used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and psoriasis; the composition of the present invention containing eculizumab (anti-complement component C5 agent) can be used to treat paroxysmal nocturnal hemoglobinuria (PNH), non Classic hemolytic uremic syndrome (aHUS) and neuromyelitis optica; the composition of the present invention comprising omalizumab (anti-IgE agent) can be used to treat asthma and chronic idiopathic urticaria; the composition of the present invention comprising cetuximab and panitumumab (anti-EGFR agents) can be used to treat colorectal cancer; the composition of the present invention comprising remanezumab (e.g., remanezumab-vfrm), ganezumab (e.g., ganezumab-gnlm) and eprenaizumab (e.g., eprenaizumab-jjmr) (calcitonin gene-related peptide (CGRP) inhibitors) can be used to treat migraine.

[0210] The compositions of the present invention comprising the relevant enzymes can be used for a variety of conditions, such as glycogen storage disease (α-glucosidase), lipid storage disease (α-D-galactose A and β-glucocerebrosidase), mucopolysaccharidosis (α-L-iduronidase and iduronic acid-2-sulfatase), mucopolysaccharidosis (N-acetylgalactosamine-6-sulfatase and N-acetylgalactosamine-4-sulfatase), various pancreatic diseases, including cystic fibrosis, Schwartz syndrome, chronic pancreatitis, pancreatic tumors or removal of all or part of the pancreas (PEP), acute myocardial infarction (alteplase, reteplase and tenecteplase ), cystic fibrosis (dornase alfa), chronic gout (begolicase), tumor lysis syndrome (rasburicase), leukemia (L-asparaginase), collagen-based disorders such as Dupuytren's contracture (collagenase), severe combined immunodeficiency disease (pegarinase, bovine), methotrexate detoxification (brancarbidase), vitreomacular adhesion (octoplasm), acute myocardial infarction (alteplase, reteplase, and tenecteplase), cystic fibrosis (dornase alfa), chronic gout (begolicase), tumor lysis syndrome (rasburicase), and L-leukemia (asparaginase).

[0211] Compositions of the invention comprising vaccines may be used to treat relevant conditions in which it is intended to elicit an immune response, including any of those described above.

[0212] As mentioned above, the compositions of the present invention may also include one or more alkyl saccharides, or may also be administered together with one or more alkyl saccharides. It was found that the compositions of the present invention comprising alkyl saccharides can exhibit unexpectedly good bioavailability and absorption rate compared to corresponding compositions that do not include, for example, alkyl saccharides and / or include different excipients known to act as surfactants.

[0213] Alkyl sugars that may be used include alkyl glycosides, which may be defined as any sugar attached to an alkyl group via a bond, such as C 7-18 Alkyl glycosides. Thus, the alkyl glycosides may include alkyl maltosides (such as dodecyl maltoside), alkyl glucosides, alkyl sucroses, alkyl thiomaltosides, alkyl thioglycosides, alkyl thiosucroses and alkyl maltotriose. However, we prefer that the alkyl sugars are sugar esters.

[0214] Sugar esters useful in the compositions of the invention include trisaccharide esters such as raffinose esters; monosaccharide esters such as glucose esters, galactose esters and fructose esters; and / or preferably disaccharide esters such as maltose esters, lactose esters, trehalose esters, and especially one or more sucrose esters.

[0215] The sucrose esters that can be used in the composition of the present invention have a hydrophilic-lipophilic balance value between 6 and 20. The term 'hydrophilic-lipophilic balance (HLB)' is a technical term that will be well understood by those skilled in the art (see, for example, 'The HLB System: A Time-Saving Guide to Emulsifier Selection' published by ICI Americas Inc, 1976 (revised in 1980), in which Chapter 7 (pages 20-21) provides a method for determining the HLB value). The longer the fatty acid chain in the sucrose ester and the higher the degree of esterification, the lower the HLB value. Preferably, the HLB value is between 10 and 20, more preferably between 12 and 20.

[0216] Sucrose esters therefore include C 8-22 Saturated or unsaturated fatty acid esters, preferably saturated fatty acid esters, and preferably C 10-18 Fatty acid esters, and most preferably C 12 Fatty acid esters. Particularly suitable fatty acids from which such sucrose esters can be formed include erucic acid, behenic acid, oleic acid, stearic acid, palmitic acid, myristic acid and lauric acid. A particularly preferred fatty acid of this type is lauric acid. Commercially available sucrose esters include those sold under the trademark and (Mitsubishi-Kagaku Foods Corporation, Japan).

[0217] The sucrose ester may be a diester or a monoester of a fatty acid, preferably a monoester, such as sucrose monolaurate. Those skilled in the art will appreciate that the term 'monolaurate' refers to a monoester of lauric acid, and that the terms 'lauric acid ester' and 'laurate' have the same meaning and may therefore be used interchangeably. Commercially available sucrose monolaurate products are sometimes also referred to as 'sucrose laurate'. Commercially available sucrose monolaurate (or sucrose laurate) products, such as sucrose monolaurate, may contain small amounts of diesters and / or higher sucrose esters as well as trace amounts of other sucrose esters and free sucrose, D-1216 (Mitsubishi-Kagaku Foods Corporation, Japan), is suitable for use in the present invention. Those skilled in the art will understand that any reference to a specific sucrose ester herein includes commercially available products comprising that sucrose ester as a major component.

[0218] Preferably, the sucrose ester contains only one sucrose ester, which means a single sucrose ester (e.g. a commercially available sucrose ester product) contains a single sucrose ester as the major component (commercially available products may contain impurities, e.g. a monoester product may contain small amounts of diesters and / or higher esters, such products may be considered to 'contain only one sucrose ester' in the context of the present invention). As used herein, the term 'major component' will be understood to refer to the major component (e.g. greater than about 50%, such as about 70% weight / weight or volume / volume) in a mixture of sucrose esters (such as a commonly commercially available surfactant product, which is typically sold with a range of ester compositions).

[0219] A particularly preferred sucrose ester is sucrose monolaurate.

[0220] Whether included in the composition of the present invention or in a final dosage form comprising one or more compositions of the present invention, the amount of alkyl saccharide that can be used can be in the range of about 0.1 wt % to about 10 wt %, such as about 0.5 wt % to about 5 wt %, preferably about 0.75 wt % to about 3 wt % (e.g. to about 2 wt %, such as about 1 wt %) based on the total weight of the composition.

[0221] Furthermore, optional additional excipients may be employed in or administered together with the compositions of the invention comprising one or more (additional) surfactants. Surfactants that may be mentioned include polyoxyethylene esters (e.g. Myr TM ), including polyethylene glycol 8 stearate (Myrj TM S8), polyethylene glycol 32 stearate ( 48 / 16), polyethylene glycol 40 stearate (Myrj TM S40), polyethylene glycol 100 stearate (Myrj TM S100) and polyethylene glycol 15 hydroxystearate ( HS15), polyoxyethylene alkyl ether (such as Brij TM ), including polyethylene glycol hexadecyl ether (e.g. Brij TM CS12, CS20 and CS25), polyethylene glycol lauryl ether (such as Brij TM L9 and L23) and polyethylene glycol octadecyl ether (such as Brij TM S10 and S20) and polyoxyglycerol esters (e.g. ), including lauroyl polyoxylglycerides ( 44 / 14) and octadecanoyl polyoxylglyceride ( 50 / 13), sorbitan esters (such as Span TM ), including sorbitan monopalmitate (Span TM40) and sorbitan monostearate (Span TM 60), polysorbate (Tween TM ), including polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate) and polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate) and sodium lauryl sulfate; and monoacylglycerols (monoglycerides), such as 2-oleylglycerol, 2-arachidonylglycerol, monolaurin, glyceryl monomyristate, glyceryl monopalmitate, glyceryl hydroxystearate, and preferably glyceryl monostearate, glyceryl monooleate (e.g. ) and glycerol monocaprylate (e.g. ). Other surfactants may include lauryl lactate, dipalmitoylphosphatidylcholine (DPPC), and poloxamers.

[0222] Other optional additional ingredients (excipients) that may be included in or administered with the compositions of the present invention include isotonic and / or osmotic agents (e.g., sodium chloride), sterols (or steroids), such as cholesterol and plant sterols (e.g., campesterol, sitosterol, and stigmasterol); antioxidants (e.g., sodium metabisulfite, or in addition, α-tocopherol, ascorbic acid, potassium ascorbate, sodium ascorbate, ascorbyl palmitate, butylated hydroxytoluene, butylated hydroxyanisole, dodecyl gallate, octyl gallate, propyl gallate, ethyl oleate, monothioglycerol, vitamins succinate or thymol); chelating (complexing) agents (e.g., edetic acid (EDTA), citric acid, tartaric acid, malic acid, maltitol and galactose, including the salt form of any of these agents); preservatives (e.g., benzalkonium chloride, or in addition, benzyl alcohol, boric acid, parabens, propionic acid, phenol, cresol or xylitol); viscosity modifiers or gelling agents (such as cellulose derivatives, including hydroxypropyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, etc., starch and modified starch, colloidal silicon dioxide, aluminum metasilicate, polycarbophil (e.g. ), carbomer (e.g. ) and polyvinylpyrrolidone); mucoadhesive polymers such as carboxymethylcellulose, modified cellulose gum and sodium carboxymethylcellulose (NaCMC); starch derivatives such as moderately cross-linked starch, modified starch and sodium starch glycolate; cross-linked polyvinylpyrrolidone, acrylic acid polymers such as carbomer and its derivatives (polycarbophil, etc.); polyethylene oxide (PEO); chitosan (poly-(D-glucosamine)); natural polymers such as gelatin, sodium alginate, pectin; scleroglucan; xanthan gum; guar gum; poly-co-(methyl vinyl ether / maleic anhydride); and cross-linked carboxymethylcellulose (e.g., cross-linked carboxymethylcellulose sodium); pH buffers (e.g., citric acid, maleic acid, malic acid, or glycine or their corresponding salts, such as sodium citrate); colorants; penetration enhancers (e.g., isopropyl myristate, isopropyl palmitate, pyrrolidone, or tricaprylin); other lipids (neutral and polar); aromatic carboxylic acids, such as benzoic acid, optionally substituted with one or more groups selected from the group consisting of methyl, hydroxyl, amino, and / or nitro groups, such as toluic acid or salicylic acid; and, if appropriate, flavorings (e.g., lemon, mint powder, or, preferably, menthol), sweeteners (e.g., neohesperidin, acesulfame K, or, preferably, sucralose) and dyes. Other excipients may include trisaccharides (eg, raffinose) and mannitol, and pH adjusters (eg, hydrochloric acid and sodium hydroxide).

[0223] The total amount of such 'additional' excipients (including surfactants which are not alkyl saccharides which may be present in the composition of the invention) which may be included with the composition of the invention itself (regardless of the dosage form in which it is contained) may also be up to about 15 wt % (e.g. about 10 wt %), such as up to about 5 wt %, based on the total weight of the composition.

[0224] For example, if one or more additional excipients are fillers or carriers in tablets, films, etc., the total amount of such 'additional' excipients that may be included in the final dosage form comprising one or more compositions of the invention may be up to about 99.99%, such as up to about 99.9%, including up to about 99%, for example up to about 90%.

[0225] Those skilled in the art will appreciate that if any additional optional ingredients are included in the composition of the invention, the nature of these ingredients and / or the amounts of these ingredients included should not have an adverse effect on the Tg of the composition for the reasons described above. In this regard, such optional ingredients may be incorporated into the spray drying process (i.e., mixed with the active ingredient and carrier material in a suitable volatile solvent and then spray dried), or may be included separately into the spray dried plurality of particles.

[0226] According to a further aspect of the invention there is provided a composition of the invention for use in medicine (human and veterinary) and therefore in the treatment of a patient in need of medical treatment for a condition for which the relevant active ingredient is known to treat.

[0227] 'Treatment' of such conditions includes prevention or diagnosis of such conditions, in addition to therapeutic, symptomatic and palliative treatment.

[0228] The compositions of the present invention can be applied by any suitable administration means known to those skilled in the art. The compositions of the present invention can be applied transmucosally, and in particular intranasally, by suitable transnasal applicators or dispenser means, which are capable of applying a suitable dose of active ingredients in the form of one or more compositions of the present invention to the nasal cavity.

[0229] Thus, suitable nasal administration members and / or applicators should be capable of containing and storing one or more doses of the relevant composition of the present invention itself, or be capable of being connected to a reservoir / container that contains and stores one or more doses of the composition of the present invention, and do so without causing significant loss of the physical and chemical integrity of the composition (including through water ingress). In this way, once the applicator device is actuated by the end user (whether this is a single dose or multiple dose use), the composition will be available, and the applicator will then deliver a composition (e.g., powder) having an appropriate dose of the active ingredient as defined herein to the subject's nasal mucosa.

[0230] Suitable applicator members have been described in the prior art. When used with a composition of the present invention, such composition may be loaded into a reservoir connected to or forming part of such an applicator member, whereupon the composition is contained until the applicator member or dispenser is actuated. Hereinafter, the terms 'applicator', 'dispenser', 'device', 'applicator member', 'dispensing member', 'applicator device', 'dispensing device' and 'insufflator' are used interchangeably and mean the same thing.

[0231] The reservoir containing the solid multiparticulate powder composition of the present invention may be opaque.Because of the stability of the composition of the present invention, there is no need to inspect the contents of the reservoir (ie, the powder composition) prior to administration or use.

[0232] Those skilled in the art will appreciate that the term 'opaque' includes 'not transparent or translucent, not light-transmissive and / or not allowing light to pass through'.

[0233] Thus, an applicator comprising a composition of the present invention does not include (or need not include) an inspection window through which the contents of the reservoir of the applicator can be viewed, and in this regard may be completely opaque, i.e., at least about 98%, such as at least about 99%, and particularly about 99.9% opaque, and / or no more than about 2%, such as no more than about 1%, and particularly about 0.1% transparent, translucent and / or light-transmissive in nature to allow inspection of the contents of the reservoir.

[0234] Such applicator means may therefore also include a mechanism for expelling a powder composition as described herein from the reservoir through an outlet means comprising an object sized to be placed in a human body cavity such as a nostril, such as a nozzle of an appropriate shape.

[0235] Thus, the mechanism for expelling powder may comprise means for actuating the device, which may comprise a breath activated actuator, or an actuation member for generating a force when the device is actuated by a user.

[0236] Thus, the applicator should be able to provide in a single application step (and in such a way that the device does not need to be 'primed') a reproducible and sufficient amount of the powder composition which will provide a therapeutic dose of the active ingredient.

[0237] Nasal administration / inhalation devices that can be used to administer the compositions of the present invention in powder form can include multi-dose administration, such as metered dose inhalation devices (MDIs), dry powder inhalation devices (DPIs; including lower, medium and higher resistance DPIs) and soft mist inhalation devices (SMIs), which can be adjusted based on techniques known in the art for delivering active ingredients to the lungs.

[0238] In an MDI, the composition of the invention should be capable of forming a stable suspension when suspended in a solvent commonly employed therein, such as a propellant having a vapor pressure sufficient to form an aerosol (e.g., a hydrocarbon, fluorocarbon, hydrofluorocarbon, or mixtures thereof) upon actuation of the delivery device.

[0239] However, if the nasal applicator is a single-dose applicator from which the composition is dispensed after actuation and then discarded after use, suitable applicator components or devices for delivering a single dose of the active ingredient include breathing-assist and insufflation-assist devices (such as ), and the applicators described in US 6,398,074, US 6,938,798 or US 9,724,713, the relevant disclosures of all documents are hereby incorporated herein by reference. Figure 1 and Figure 2 Based on US 6,398,074 Figure 1 and Figure 2 ,and Figures 3 to 7 Based on Figures 19 to 23 of US 9,724,713 respectively. Both are illustrations of applicators that may be used to administer the composition of the invention intranasally.

[0240] exist Figure 1In the embodiment of the present invention, the device comprises an upper body / dispenser head 1 incorporating an outlet channel 40 (i.e. part of the 'outlet member' as described above) and a gripping member 60 allowing the user to actuate the device. Inside the upper body / dispenser head 1 there is mounted an element, indicated in its assembly by reference numeral 2, incorporating a reservoir 10 and an air chamber 22 for an air jet 20. This element 2 is possibly produced in one piece with the body 1. A lower body 3 is also provided so as to be able to slide relative to the upper body 1 and relative to the element 2, to which the user applies a pushing force to actuate the device.

[0241] The reservoir 10 contains a single dose of the composition of the invention. The reservoir 10 has an air inlet 11 and a product outlet 15. A product retaining device 12 comprising an air-permeable mesh is arranged in the air inlet 11 to retain the product in the reservoir 10 until the composition is dispensed. The product outlet 15 is blocked, preferably in a sealed manner, by a blocking ball 16 which is moved from its blocking position by the air flow when the applicator is actuated and the product is dispensed.

[0242] When the user actuates the device, pressure is applied to the plunger 25 in such a way that the piston 21 compresses the air 20 contained in the chamber 22. Since the grid 12 is air-permeable, the compression of the air in the chamber 22 generates a jet of air which is transmitted to the reservoir 10 and is therefore applied to the blocking ball 16 which is blocking the product outlet 15.

[0243] The dimensions of the blocking ball 16 and its fixing at the reservoir product outlet 15 are such that the ball 16 moves from its blocking position when a minimum predetermined pressure is generated by the blast of air 20 through the reservoir 10 .

[0244] The pre-compression created by the blocking ball 16 ensures that when the blocking ball is removed from its blocking position, the energy accumulated in the user's hand causes the piston 21 integral with the plunger 25 to be pushed within the chamber 22, thereby generating a powerful jet of air 20, that is, an air flow suitable for finely spraying a dose of the composition of the present invention.

[0245] When this minimum pressure is reached, the ball moves rapidly towards the outlet channel 40 of the device and the air flow 20 generated by the air jet expels substantially the entire dose of the composition of the invention contained in the reservoir 10 .

[0246] Preferably, the diameter of the outlet passage 40 is greater than the diameter of the stopper ball 16 so as to allow the dose of product to be discharged through the outlet passage 40 by flowing around the ball 16. Figure 2 As shown, which shows the same device after actuation, the passage 40 includes a member 41 which blocks or secures the ball 16 so as to prevent it from being ejected from the device when the product is ejected.

[0247] Additional examples of compositions of the present invention that can be administered intranasally are provided in US Pat. No. 9,724,713, col. 7, line 50 to col. 8, line 61 and FIGS. 19 to 23, which are reproduced herein. Figures 3 to 7 .

[0248] In this embodiment, the reservoir 10 is secured in an upper body / dispenser head 1 including a dispenser outlet passage 40 (i.e. part of the 'outlet member' as described above), which has a gripping member or finger rest 60 which allows the user to actuate the device. The radial shoulder 37 of the upper body / dispenser head 1 (see Figure 5 ) advantageously defines said assembled position of the reservoir 10 in the upper body / dispenser head 1 .

[0249] The mechanical opening system comprises a set of rods 61, 62, wherein when the device is actuated, a second rod portion 62 is pushed by said first rod portion 61. At the end of its actuation stroke, i.e. in the dispensing position, this set of rods 61, 62 cooperates with a blocking element 16, which is spherical, in particular a ball as in the first embodiment described above, in order to mechanically expel it from its closed position.

[0250] In this embodiment, the piston 21 is separate from the first rod portion 61 and slides both relative to the air chamber 22 and relative to the cylindrical surface 614 fastened to the first rod portion 61 . Figure 7 for Figures 3 to 6 A diagrammatic perspective view of an air expeller of the device in its rest position.

[0251] The air cavity 22 may thus be cylindrical and in its rest position communicate with the ambient air at grooves or recesses 615 formed in said cylindrical surface 614 and cooperating with the piston 21, in particular in its rest position. The piston 21 thus comprises an inner lip 215 which slides on the cylindrical wall 614 in an airtight manner during actuation and in its rest position cooperates with said groove 615. The piston 21 also comprises an axial extension 216 which cooperates with a top edge 251 of a push rod element 25 (referred to as 'plunger' in the first embodiment) which moves said piston 21 in the air cavity 22 during actuation.

[0252] The retainer element 42 extends downwardly by an axial extension 43 which, during actuation, comes into contact with the top axial end 610 of the first shaft portion 61 .

[0253] Furthermore, in this embodiment, there is no outer body, but only a cover 27 assembled on the bottom axial edge of the air cavity 22 .

[0254] A spring 80 is provided between the radial flange 225 of the air cavity 22 and the portion forming the first rod portion 61 and the cylindrical surface 614 in order to automatically return the air expeller into its rest position after actuation.

[0255] The operating principle is as follows. Figure 3 In the rest position in the piston 21, the reservoir 10 is closed in a sealed manner by the retainer element 42 and by the stopper element / ball 16. The air expeller is open to the atmosphere by cooperation between the inner lip 215 of the piston 21 and the groove 615 of the cylindrical surface 614.

[0256] When it is desired to actuate the device, the user presses the push rod element 25. During this initial stroke, the inner lip 215 of the piston leaves the groove 615 to cooperate in an airtight manner with the cylindrical surface 614, thereby closing the air chamber 22. At the same moment, the top edge 251 of the push rod element 25 comes into contact with the axial extension 216 of the piston 21, and the top axial end 610 of the first rod portion 61 comes into contact with the axial extension 43 of the retainer element 42.

[0257] However, the top axial end 621 of the second rod portion 62 is still not in contact with the circular surface 55 of the stop element / ball 16, as shown in FIG. Figure 4 Visible in.

[0258] Continuous actuation thus simultaneously moves the piston 21 in the air chamber, compressing the air contained therein, and moves the retainer element 42 away from its position closing the reservoir 10. When the second rod portion 62 contacts the circular surface 55 of the stopper element / ball 16, said stopper element / ball is mechanically expelled from its closed position, so as to enable the composition to be expelled under the action of the air compressed by the air expellor.

[0259] The allocation location is shown in Figure 5 In. Figure 5 As can be seen in the figure, when the composition is expelled under the action of compressed air provided by the air expeller, the retainer element 42 may be separated from the first rod portion 61. In this position, the blocking element / ball is expelled from the reservoir 10 so as to enable the fluid or powder to be dispensed under the action of compressed air. Therefore, the blocking element / ball 16 is stuck in the splines 3 of the upper body / dispenser head 1, which in particular prevent any risk of the blocking element / ball 16 being expelled from the upper body dispenser head 1.

[0260] When the user releases the device, Figure 6As shown in , the spring 80 compressed during braking returns the first rod portion 61 toward its resting position. This produces suction, which sucks the blocking element 16 and the retainer element 42 back toward its blocking position or sucks it back to near its blocking position. This therefore blocks the path of new suction, so as to avoid contaminating the air ejector when the air ejector automatically returns to its resting position, and the empty reservoir is still assembled on the air ejector. However, the piston 21 is maintained in its distribution position due to the friction with the air chamber 22 and the suction generated in the reservoir 30, so that the cylindrical surface 614 slides on the inner lip 215 of the piston until the inner lip cooperates with the groove 615 again. At this point, the air chamber 22 is communicated with the ambient air again, and no longer produces suction due to returning to the resting position. Therefore, the piston 21 is also entrained toward its resting position. This makes it possible to close the reservoir after use.

[0261] Alternatively, the unit formed by the upper body / dispenser head 1 and the empty reservoir 10 may be removed from the air expeller and replaced by a new unit comprising a full reservoir.

[0262] Suitable applicator devices that can be used include those available from Aptar Pharma, France (UDS Monopowder). See, for example, international patent applications WO 2022 / 208014 and WO 2021 / 005311. Other examples of applicator devices that can be used in conjunction with the compositions of the present invention (especially those in powder form) include those described in U.S. Patent Application US 2011 / 0045088, U.S. Patent No. US 7,722,566 (see, for example, Figure 1 and Figure 7 ) and US 5,702,362 and those in international patent application WO 2014 / 004400, the relevant disclosures of which are hereby incorporated by reference.

[0263] According to a further aspect of the invention there is provided a method for manufacturing an applicator device comprising a composition of the invention, wherein the method comprises the step of loading the composition into a reservoir within or attached to the applicator device.

[0264] According to a further aspect of the present invention, there is provided a needle-free applicator suitable for administering the solid amorphous single particle powder composition of the present invention into a body cavity of a human patient, the cavity comprising a mucosal surface, wherein the applicator comprises:

[0265] (i) a (optionally opaque) reservoir within or attached to the applicator comprising the composition of the invention;

[0266] (ii) an optional actuation member for generating a force when the device is actuated by a user; and

[0267] (iii) a dispensing member through which said powder composition can be dispensed following said actuation.

[0268] According to another aspect of the present invention, there is provided an applicator and / or dispenser device comprising one or more compositions of the present invention in powder form, the applicator or device being actuable one or more times to deliver one or more compositions of the present invention each comprising an appropriate dose of active ingredient upon each such actuation, the applicator / dispenser device comprising:

[0269] an outlet through which at least one composition is dispensed;

[0270] A means for generating a force (e.g., air flow) from the outside when the device is actuated by a user;

[0271] at least one (optionally replaceable) reservoir containing said one or more compositions of the invention, said reservoir being in direct or indirect communication with said dispenser outlet or being capable of being placed in direct or indirect communication with said dispenser outlet;

[0272] a displaceable, optionally reversible, sealing member in the device and / or reservoir for retaining the one or more compositions within the reservoir until the composition is dispensed;

[0273] a mechanical opening system cooperating with the sealing member so that when the device is actuated, a single composition of the invention is mechanically expelled by the force member; and

[0274] Optionally, a mechanism for resealing the device and / or reservoir to retain the additional composition within the reservoir until the additional composition is dispensed.

[0275] According to still a further aspect of the present invention, there is provided an applicator and / or dispenser device containing a single dose of a composition of the present invention, which is suitable for dispensing the composition, the applicator / dispenser device comprising:

[0276] Distributor outlet;

[0277] an air expeller for generating an air flow when the device is actuated, the air expeller comprising a piston sliding in the air chamber between a rest position and a dispensing position;

[0278] The piston slides in the air chamber in an airtight manner;

[0279] at least one reservoir containing a dose of a composition of the invention, said reservoir comprising an air inlet connected to said air expeller;

[0280] a composition outlet connected to the dispenser outlet;

[0281] The air inlet includes a displaceable sealing member (e.g., a retainer element) for retaining the composition in the reservoir until the composition is dispensed;

[0282] The composition outlet is closed by a blocking element adapted in the composition outlet of the reservoir;

[0283] The device further comprises a mechanical opening system cooperating with the blocking element to mechanically expel the blocking element from its closed position when the device is actuated; and

[0284] The piston of the air expeller cooperates with the air chamber in a non-airtight manner when in its rest position.

[0285] In the latter aspect of the invention, it is preferred that:

[0286] (i) the air chamber in which the piston slides in an airtight manner is substantially cylindrical;

[0287] (ii) the blocking element is forcibly fitted into the composition outlet of the reservoir;

[0288] (iii) the air cavity is in communication with the atmosphere in the rest position; and / or

[0289] (iv) the piston comprises an inner lip adapted to cooperate with a cylindrical surface, the cylindrical surface comprising a groove cooperating in a non-gas-tight manner with the inner lip of the piston in the rest position.

[0290] Such nasal applicators or dispensing devices are capable of providing an appropriate and reproducible powder spray pattern and / or plume geometry that enables effective delivery of the powder to the nasal cavity (eg, nostrils).

[0291] In the compositions of the present invention, the average particle size may be presented as an average diameter based on weight, number or volume. As used herein, the term 'average diameter based on weight' will be understood by the skilled person to include that the average particle size is characterized and defined by a particle size distribution by weight, i.e. a distribution in which the existing fraction (relative amount) in each size class is defined as a weight fraction, as obtained by, for example, sieving (e.g., wet sieving). The term 'average diameter based on volume' is similar in its meaning to the average diameter based on weight, but will be understood by the skilled person to include that the average particle size is characterized and defined by a particle size distribution by volume, i.e. a distribution in which the existing fraction (relative amount) in each size class is defined as a volume fraction, as measured by, for example, laser diffraction. As used herein, the term 'average diameter based on number' will be understood by the skilled person to include that the average particle size is characterized and defined by a particle size distribution by number, i.e. a distribution in which the existing fraction (relative amount) in each size class is defined as a number fraction, as measured by, for example, microscopy. Particle size may be measured using other instruments well known in the art, such as equipment sold by, for example, Malvern Instruments, Ltd (Worcestershire, UK), Sympatec GmbH (Clausthal-Zellerfeld, Germany), and Shimadzu (Kyoto, Japan).

[0292] Although particle size is not (or rather may not be) critical when the compositions of the invention are formulated for administration, e.g., orally, topically to the oral cavity, eye or other mucosa, or by injection or infusion, the powder compositions of the invention will generally have a volume-based mean diameter (VMD) in the range of about 0.2 μm (such as about 0.5 μm, e.g., about 1 μm) to up to about 1,000 μm (e.g., to up to about 500 μm, such as about 400 μm or about 500 μm), and the appropriate particle size range may be selected based on the dosage form intended to include such a composition.

[0293] However, those skilled in the art will appreciate that to allow for effective intranasal administration, the powder will typically have a volume-based mean diameter (VMD) in the range of about 5 μm to up to about 300 μm (e.g., up to about 200 μm). Depending on the applicator device employed, the VMD may be in the range of about 10 μm to about 100 μm, such as about 20 μm to about 60 μm.

[0294] Preferred particle size distributions for intranasal drug delivery may also include those in which D10 is above about 3 μm and below about 75 μm (e.g., up to about 50 μm), such as greater than about 10 μm, and D90 is between about 80 μm and about 1,000 μm (e.g., about 500 μm), such as below about 100 μm. Those skilled in the art will understand that the parameter 'D10' (or 'Dv(10)') means the size (or diameter) in a particle size distribution below which 10% of the total volume of the material in the sample is contained. Similarly, 'D90' (or 'Dv(90)') means the size below which 90% of the material is contained.

[0295] Those skilled in the art will appreciate that to allow for effective pulmonary administration, the powder will generally have a VMD in the range of about 0.2 μm up to about 10 μm.

[0296] Reference to powders having a particle size distribution and VMD within the above ranges includes bulk VMD and / or VMD as emitted, ie, the particle size distribution when initially loaded into the device and / or when discharged from the device, respectively.

[0297] Particle size can be measured by standard equipment, such as dry (or wet) particle size measurement techniques, including dry dispersion techniques available from manufacturers such as Sympatec and Malvern.

[0298] Preferred particle shapes include spherical or substantially spherical, meaning that the particles have an aspect ratio of less than about 20, more preferably less than about 10, such as less than about 4, and especially less than about 2, and / or may have a radius variation (measured from the center of gravity to the particle surface) of no more than about 50% of the average value, such as no more than about 30% of this value, for example no more than about 20% of this value in at least about 90% of the particles.

[0299] However, the particles may be of any shape, including irregular shapes (eg, 'raisin' shapes), needle-shaped, disc-shaped or cuboid-shaped particles. For non-spherical particles, the size may be indicated as, for example, the size of a corresponding spherical particle of the same weight, volume or surface area.

[0300] The spray angle of the powder composition of the present invention emitted (dispensed) from the nasal applicator and / or dispenser device should preferably be less than about 90°.

[0301] When the word 'about' is used herein in the context of an amount, e.g., an absolute amount, such as a dose, weight, volume, size, diameter, aspect ratio, angle, etc., or an individual ingredient in a composition or a relative amount (e.g., percentage) of a component of a composition (including concentrations and ratios), a time frame, and a parameter such as temperature, pressure, relative humidity, etc., it will be understood that such variables are approximate and may therefore vary from the actual number specified herein by ±10%, e.g., ±5%, and preferably ±2% (e.g., ±1%). This is true even if such numbers are initially presented as percentages (e.g., 'about 10%' may mean about ±10% of the number 10, which is any number between 9% and 11%).

[0302] The compositions of the present invention have the advantage that they can be prepared under a wide range of temperatures and relative humidities and thereafter stored without significant loss of biological activity. Thus, the compositions of the present invention can withstand low temperatures (e.g., below freezing) without affecting the amount of active ingredient administered to a subject. In addition, the compositions of the present invention may have the advantage that they are more physically and chemically stable at higher temperatures than related prior art compositions.

[0303] The compositions of the present invention may also further have the advantage that they provide active ingredients with higher bioavailability than prior art compositions. The compositions of the present invention may provide this higher bioavailability as well as faster absorption, which will likely result in a faster onset of action than such prior art and / or commercially available compositions, and thus meet a significant medical need.

[0304] The compositions, pharmaceutical formulations, uses and methods described herein may also have the following advantages: in the treatment of conditions for which the relevant active ingredients are known, they may be more convenient for first responders, physicians and / or patients, more effective, less toxic, have a broader spectrum of activity, be more potent, produce fewer side effects, have less inter-patient variability, or it / they may have other useful pharmacological properties, whether used by transmucosal (such as intranasal) administration or otherwise in the treatment of the aforementioned conditions, compared to similar formulations or methods (treatments) known in the prior art.

[0305] The present invention is illustrated by the following examples with reference to the accompanying drawings, but is in no way limiting of the present invention. Figures 1 to 7 a diagram showing an actuator device that can be used to dispense a powder composition, and Figure 8 and Fig. 9 Shown is the retained activity of the SARS-CoV-2 RBD spike protein under different conditions after forming a spray-dried powder compared to the activity of the same protein on the initial solution before spray drying.

[0306] Example 1

[0307] Composition I of the present invention

[0308] Six formulations, each approximately 2 g of powder, were prepared by adding the required amount of lyophilized β-galactosidase (lactase; 5000 units / mg; Merck / Sigma Aldrich Germany) and the following excipients: trehalose (Merck / Sigma Aldrich, Germany), maltodextrin (MD) IT12 and IT19 (Roquette, France), sucrose laurate D1216 (SL; Mitsubishi Chemicals, Japan) and HPMC K3 (Dupont, USA) to 30 mL glass vials. The compositions are shown in Table 1 below (where individual components are in wt %).

[0309] Table 1

[0310] <![CDATA[ Preparations ]]> <![CDATA[ Lactase ]]> <![CDATA[ Trehalose ]]> <![CDATA[ MD IT12 ]]> <![CDATA[ MD IT19 ]]> <![CDATA[ SL ]]> <![CDATA[ HPMC ]]> 1 0.61 40.0 52.3 0 3.05 0 2 1.22 40.0 51.7 0 3.05 0 3 1.22 40.0 0 53.3 1.49 0 4 0.61 40.0 47.4 0 3.05 4.80 5 0.61 40.0 52.3 0 3.05 0 6 0.61 40.0 0 53.9 1.49 0

[0311] The vials were then placed in a freezer maintained at -20° C. Prior to shipment, the vials were placed in aluminum bags with desiccant (molecular sieves) and placed in an insulated box with wet ice.

[0312] Spray drying was performed at Xedev (Belgium) using a ProCepT spray dryer with an elongated column. A total of 12 samples were produced from the six formulations prepared by varying the nozzle type and process conditions. An overview of the spray drying process is shown in Table 2 below.

[0313] Before spray drying, the six prepared formulations were dissolved in water, where the resulting solid content (w / w%, water: solid) ranged between 5% and 10%. From these solutions, 0.5 mL was extracted from each vial into a separate LC vial and placed in a freezer before shipment. These were reference solutions for determining enzyme activity before spray drying.

[0314] The feed rate of the solution was set to 4 g / min, resulting in processing times of between 1 min and 5 min for the samples shown in Table 2. To reduce possible heat exposure during processing, an ice bath was used to freeze the collection container during some runs.

[0315] Table 2

[0316]

[0317]

[0318] Notice

[0319] 1. 'Open' means open to air; 'Closed' means under nitrogen

[0320] 2. Inlet temperature at the spray nozzle

[0321] 3. The outlet temperature at the outlet of the cyclone

[0322] After spray drying, the samples were placed in a freezer until shipped. The samples were shipped under the same conditions as described above, i.e., using a dehumidifier and wet ice.

[0323] Enzyme activity was measured using 2-nitrophenyl β-D-galactoside (ONPG; Merck / Sigma Aldrich, Germany) as a substrate for the enzyme.

[0324] Prior to the assay, 100 mg of each spray-dried material was transferred to a separate LC vial and diluted to the same concentration as the reference solution (see above).

[0325] The enzyme solution, reference and spray-dried powder were diluted with PBS (pH 7.4) and thereafter 5 mM MONPG was added in excess. The UV / vis absorbance of the mixture was measured at 420 nm at 0.5, 1, 2, 3, 4 and 5 minutes. This operation was performed in duplicate.

[0326] The absorbance of the spray-dried solution was compared to the corresponding reference solution using linear regression. The reference solution was designated as having 100% activity, and the quotient of the slope was used to determine the retained activity of the spray-dried solution. The results are presented in Table 3 below. (Note that the results for Sample 001 and Sample 002 were excluded because there was some uncertainty about the integrity of the reference samples).

[0327] Table 3

[0328]

[0329]

[0330] Notice

[0331] 1. Activity = slope of spray-dried sample / slope of reference sample x 100

[0332] The results show that according to the present invention, the loss of activity of the enzyme followed by the spray drying process is minimal.

[0333] Example 2

[0334] Composition II of the present invention

[0335] Twelve formulations, each approximately 2.5 to 2.6 g of powder, were prepared by adding the required amount of lyophilized SARS-CoV-2 RBD spike protein (L452R), His tag ('S protein'; SPD-C52He, ACRO Biosystems, US) and the following excipients to a 100 mL glass flask: trehalose dihydrate (Pfanstiel, US), maltodextrin (MD) IT19 (Roquette, France), sucrose laurate D1216 (SL; Mitsubishi Chemicals, Japan), phosphate buffered saline (PBS) and pure deionized water (5% solid content). The formulations had the compositions shown in Table 4 below (wherein the individual components are in wt %).

[0336] Table 4

[0337] <![CDATA[ Preparations ]]> <![CDATA[ S protein ]]> <![CDATA[ Trehalose ]]> <![CDATA[ MD IT19 ]]> <![CDATA[ SL ]]> <![CDATA[ PBS ]]> 7 0.0009 20.0 73.0 3.0 - 8 0.0009 40.0 53.0 3.0 - 9 0.0009 60.0 33.0 3.0 - 10 0.0009 80.0 13.0 3.0 - 11 0.0009 20.0 76.0 - - 12 0.0009 80.0 16.0 - - 13 0.0009 20.0 57.0 - 19 14 0.0009 61.0 16 - 19 15 0.0009 20.0 76.0 3.0 - 16 0.0009 40.0 53.0 3.0 - 17 0.0009 60.0 33.0 3.0 - 18 0.0009 80.0 53.0 3.0 -

[0338] The nominal water content in the final powder was 4%.

[0339] Spray drying was performed using a ProCepT spray dryer with an extended column using ultrasound and a two-fluid nozzle. An overview of the spray drying process is shown in Table 5 below.

[0340] Prior to spray drying, 0.8 mL of solution was extracted from each vial into individual LC vials and placed in a freezer (-20° C.) These solutions were reference solutions for determining the initial activity of the protein prior to spray drying.

[0341] The feed rate of the solution was set to 4 g / min, resulting in a processing time of about 13 min for the samples shown in Table 5.

[0342] Table 5

[0343]

[0344]

[0345] After spray drying, the samples were placed in sealed aluminum bags with desiccant and stored at -20°C until analysis. Additional powders were packaged in the same manner and stored at four different temperatures (-20°C, -5°C, 20°C and 40°C) for 4 weeks.

[0346] Protein activity was analyzed using the SARS-CoV-2 spike protein titer assay kit ELISA (RAS-A020-96TEST, ACROBiosystems, US). Prior to analysis, the spray-dried material and the initial solution were diluted to a target concentration of approximately 0.2 ng / mL, and all samples were analyzed in duplicate.

[0347] The measured retention activity of the powder after spray drying relative to the initial solution ranged from 30% (acceptable loss) to 100% (minimum loss), as Figure 8 as shown in .

[0348] A second analysis was performed after 4 weeks of storage. While some variability was noted between and within the assays (including higher activity upon storage and variability between multiple replicates), it was apparent that activity was maintained in all samples stored at all temperatures, as shown in Table 1. Fig. 9 as shown in .

Claims

1. A pharmaceutically acceptable composition in the form of a solid amorphous single particle powder composition comprising a mixture of: (a) a pharmacologically effective amount of at least one biopharmaceutical drug compound; and (b) a pharmaceutically acceptable carrier material, said carrier material comprising a combination of a disaccharide and a polymer material.

2. The composition of claim 1, wherein the polymer material comprises maltodextrin.

3. The composition of claim 1 or claim 2, wherein the disaccharide is selected from the group consisting of maltitol, trehalose, sucralose, sucrose, isomalt, maltose and lactose. The composition of claim 3 , wherein the disaccharide comprises lactose or trehalose.

5. A composition according to any one of the preceding claims, wherein the carrier material comprises a combination of trehalose and maltodextrin 19DE.

6. The composition of any of the preceding claims, wherein the ratio of disaccharide:polymer by weight is in the range of about 10:1 and about 1:10 based on the total weight of the composition.

7. The composition of claim 6, wherein the ratio of disaccharide:polymer is in the range of about 2:1 to about 1:

8.

8. The composition of any of the preceding claims, wherein the composition has a lowest measurable glass transition temperature of at least about 10°C when measured at a relative humidity of up to about 35%.

9. The composition according to any one of the preceding claims, wherein the composition further comprises a sucrose ester.

10. The composition of claim 9, wherein the sucrose ester comprises sucrose monolaurate.

11. The composition of any of the preceding claims, wherein the pharmacologically effective dose of the at least one biopharmaceutical drug compound does not exceed about 100 mg.

12. The composition according to any one of the preceding claims, wherein at least one biopharmaceutical drug compound is selected from the group consisting of proteins, oligopeptides, polypeptides, enzymes, antibodies, vaccines and nucleotides.

13. A composition according to any preceding claim which is suitable and / or adapted for nasal delivery.

14. The composition of claim 13, wherein the powder has a particle size distribution comprising a D10 above about 3 μm.

15. A composition according to claim 13 or claim 14, wherein the powder has a particle size distribution comprising a volume-based mean diameter in the range of about 10 μm and about 100 μm.

16. The composition of any one of claims 13 to 15, wherein the biopharmaceutical drug compound is a vaccine.

17. A composition according to any one of claims 1 to 12 which is suitable and / or adapted for oral delivery.

18. The composition of claim 17, wherein the biopharmaceutical drug compound is an enzyme.

19. The composition of any one of claims 1 to 12 dissolved in a pharmaceutically acceptable solvent for delivery by injection or by infusion.

20. The composition of claim 19, wherein the biopharmaceutical drug compound is an antibody.

21. A method for producing a composition as defined in any one of the preceding claims, wherein the method comprises the following steps: (i) mixing one or more biopharmaceutical drug compounds with a pharmaceutically acceptable carrier material in a suitable volatile solvent, (ii) spray drying the mixture from step i).

22. A composition obtainable by a method as defined in claim 21.

23. A nasal applicator device suitable and / or adapted for delivering a composition as defined in any one of claims 1 to 16 or 22 to the nose, said nasal applicator device comprising or being pertinent and / or attached to a reservoir, said composition being contained within said reservoir.

24. A method for manufacturing an applicator device according to claim 23, said method comprising the method according to claim 21, followed by loading the composition so formed into a reservoir within or incidental or attached to said applicator device.

25. A composition as defined in any one of claims 1 to 20 or 22 for use in the treatment of a condition for which the at least one biopharmaceutical drug compound contained therein is indicated.

26. Use of a composition as defined in any one of claims 1 to 20 or 22 for the manufacture of a medicament for the treatment of a condition for which the at least one biopharmaceutical drug compound contained therein is indicated.

27. A method of treating a condition for which at least one biopharmaceutical drug compound comprised in a composition as defined in any one of claims 1 to 20 or 22 is indicated, said method comprising administering a composition of the invention to a patient suffering from or susceptible to said condition.